

Catalog of Preference Scores

Reference #	Health State	Preference Score	Range	Preferences Determined By	Measurement Technique	Generic Scale
1. Infectious and Parasitic Diseases						
Tuberculosis (TB)						
340	Side effects causing INH discontinuation (1 month of discomfort in the institution) (assume a baseline of 1)	0.9		Not stated	Unknown	
340	Hepatitis due to INH treatment (2 months convalescence in the institution) (assume a baseline of 1)	0.9		Not stated	Unknown	
340	Tuberculosis, non-fatal, in diagnosed and treated cases (three months convalescence) (assume a baseline of 1)	0.9		Not stated	Unknown	
340	Tuberculosis, non-fatal, undiagnosed, untreated (2 months treated in the institution) (assume a baseline of 1)	0.9		Not stated	Unknown	
Varicella						
252	Chickenpox complications requiring hospitalization	0.4		Author	Author/clinician judgement	
252	Febrile chickenpox patients not hospitalized and not receiving acyclovir	0.65		Author	Author/clinician judgement	
252	Febrile chickenpox patients not hospitalized and receiving acyclovir	0.65		Author	Author/clinician judgement	
252	Nonfebrile chickenpox patients not hospitalized and not receiving acyclovir	0.7		Author	Author/clinician judgement	
252	Nonfebrile chickenpox patients not hospitalized and receiving acyclovir	0.85		Author	Author/clinician judgement	
417	Severe acute Zoster	0.7		Not stated	Unknown	
417	Mild acute Zoster	0.9		Not stated	Unknown	
417	Post-herpetic neuralgia	0.9		Not stated	Unknown	
518	Hospitalization for chickenpox	0.4		Author	Author/clinician judgement	
518	Chickenpox with fever (short term home confinement for an unnamed contagious disease)	0.65		Author	Author/clinician judgement	
518	Non-febrile chickenpox illness without aciclovir treatment	0.7		Author	Author/clinician judgement	
518	Non-febrile chickenpox illness with aciclovir treatment	0.85		Author	Author/clinician judgement	
524	hospitalized for herpes zoster	0.3		Community (n not given)	Unknown	
524	Severe symptoms of herpes zoster	0.7		Community (n not given)	Unknown	
524	Mild symptoms of herpes zoster	0.9		Community (n not given)	Unknown	
Antibiotics/General						

276	Impaired (Major loss of joint function due to bacterial arthritis)	0.75		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
276	Fatal reaction to antibiotic prophylaxis for bacterial arthritis	0.989		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
312	Vancomycin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with vancomycin toxicity	0.75		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with no vancomycin toxicity	0.85		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis with no penicillin allergy skin test and vancomycin toxicity	0.87		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis with no penicillin allergy skin test and no vancomycin toxicity	0.875		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with vancomycin toxicity	0.9		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis with no penicillin allergy skin test and vancomycin toxicity	0.92		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with no vancomycin toxicity	0.95		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis with no penicillin allergy skin test and no vancomycin toxicity	0.97		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	

312	Cloxacillin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with survived penicillin reaction	0.82		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with no penicillin reaction	0.885		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with survived penicillin reaction	0.92		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with no penicillin reaction	0.985		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
539	Serious complication due to sinusitis	0.387		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick with antibiotic side effects: Severe sinusitis	0.378		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick without antibiotic side effects: Severe sinusitis	0.498		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick with antibiotic side effects: Moderate sinusitis	0.426		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick without antibiotic side effects: Moderate sinusitis	0.56		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick with antibiotic side effects: Mild sinusitis	0.584		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Sick without antibiotic side effects: Mild sinusitis	0.769		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Cure with antibiotic side effects	0.76		Community	Rating scale	QWB Scale Not stated to whom it was given
539	Cure without antibiotic side effects of acute bacterial sinusitis	1		Community	Rating scale	QWB Scale Not stated to whom it was given
	HIV/AIDS					
229	Aware of HIV + CD4 count < 200	0.65		Patients (AIDS patients, n not stated)	Unknown	

229	Aware of HIV + CD4 count 200 - 499	0.9		Patients (AIDS patients, n not stated)	Unknown	
241	Asymptomatic HIV infection	0.9		Author	Author/clinician judgement	
241	In maintenance treatment for HIV	0.9		Author	Author/clinician judgement	
342	HIV symptomatic	0.98		Author	Author/clinician judgement	
342	HIV primary infection	1		Author	Author/clinician judgement	
342	HIV asymptomatic	1		Author	Author/clinician judgement	
371	HIV infection, 1st 6 yrs.	1		Not stated	Unknown	
450	Symptomatic HIV infection	0.77		Community	Rating scale	QWB Scale (to 139 patients with HIV)
468	HIV infection	0.75		Author	Author/clinician judgement	
257	Asymptomatic non-injection drug users who are HIV infected	0.9		Community	Rating scale; Standard gamble	Health Utilities Index (given to 73 patients with HIV)
231	Symptomatic HIV, no AIDS defining illness (ADI)	0.79		Patient (69 patients with HIV infection)	Standard gamble	
503	HIV INFECTED WITHOUT OPPORTUNISTIC INFECTION	0.65		Author	Unknown	
233	Child: HIV-infected, without AIDS, on therapy	0.79	.79-.95	Author	Unknown	
233	Mother: CD4 cell count < 200 x 10 ⁶ /l, with opportunistic infection	0.62	.62-.83	Author	Unknown	
233	Child: On therapy with AIDS	0.62	.62-.92	Author	Unknown	
233	Mother: CD4 cell count < 200 x 10 ⁶ /l, without opportunistic infection	0.65	.65-.87	Author	Unknown	
233	Mother: CD4 cell count 200-500 x 10 ⁶ /l	0.76	.76-.90	Author	Unknown	
233	Mother: CD4 cell count > 500 x 10 ⁶ /l	0.82	.82-.95	Author	Unknown	
249	HIV infection with CD4 cells/cubic-mm <100	0.63		Community	Rating scale	QWB Scale (to 139 patients with HIV)
249	HIV infection with CD4 cells/cubic-mm 100-199	0.66		Community	Rating scale	QWB Scale (to 139 patients with HIV)
249	HIV infection with CD4 cells/cubic-mm 200-349	0.69		Community	Rating scale	QWB Scale (to 139 patients with HIV)
249	HIV infection with CD4 cells/cubic-mm >500	0.72		Community	Rating scale	QWB Scale (to 139 patients with HIV)

249	HIV infection with CD4 cells/cubic-mm 350-500	0.72	Community	Rating scale	QWB Scale (to 139 patients with HIV)
329	CD4<200	0.79	Community	Rating scale; Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
329	200<CD4<500	0.82	Community	Rating scale; Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
389	HIV infection with CD4 count of 0-0.050 x 10 ⁹ /L	0.79	Patient (n not given)	Torrance transformation of rating scale	
389	HIV infection with CD4 count of 0.051-0.100 x 10 ⁹ /L	0.81	Patient (n not given)	Torrance transformation of rating scale	
389	HIV infection with CD4 count of 0.101-0.200 x 10 ⁹ /L	0.87	Patient (n not given)	Torrance transformation of rating scale	
389	HIV infection with CD4 count of 0.201-0.300 x 10 ⁹ /L	0.94	Patient (n not given)	Torrance transformation of rating scale	
371	HIV infection, with CD4 count <200/mm ³	0.65	Not stated	Unknown	
371	HIV infection, with CD4 count between 200 and 499/mm ³	0.9	Not stated	Unknown	
330	HIV-infected patient with CD4 count <200	0.79	Community	Rating scale; Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
330	HIV-infected patient with CD4 count = 200	0.82	Community	Rating scale; Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
395	Routine care for HIV infection with very low CD4 count	0.79	Patient (n not given)	Torrance transformation of rating scale	
395	Routine care for HIV infection with low CD4 count	0.807	Patient (n not given)	Torrance transformation of rating scale	
395	Routine care for HIV infection with medium CD4 count	0.872	Patient (n not given)	Torrance transformation of rating scale	
395	Routine care for HIV infection with high CD4 count	0.937	Patient (n not given)	Torrance transformation of rating scale	

462	CD4 cell count < 200/mm ³	0.8		Community	Rating scale	QWB Scale (to 139 patients with HIV)
462	CD4 cell count 200-500/mm ³	0.88		Community	Rating scale	QWB Scale (to 139 patients with HIV)
462	CD4 cell count > 500/mm ³	0.94		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
464	CD4 cell count < 200 cells/mm ³	0.84		Patient (n not given)	Torrance transformation of rating scale	
464	CD4 cell count > 200 cells/mm ³	0.94		Patient (n not given)	Torrance transformation of rating scale	
501	Pre-AIDS low CD4 cell counts	0.5	.25-.75	Not stated	Unknown	
514	HIV with CD4 < 200	0.42		Clinician (health care workers n not given)	Time trade off	
514	HIV with CD4 > 500	0.83		Clinician (health care workers n not given)	Time trade off	
514	HIV with CD4 200-500	0.83		Clinician (health care workers n not given)	Time trade off	
260	HIV-infected patients with mild adverse event after receiving TB prophylaxis for 1 week	0.5		Author	Unknown	
260	HIV-infected patients with tuberculosis	0.62		Author	Unknown	
260	HIV-infected patients with moderate to severe adverse event after receiving TB prophylaxis for three weeks	0.25		Author	Unknown	
290	PCP infection	0.3		Clinician	Author/clinician judgement	
395	HIV-infected with acute toxoplasmosis infection care	0.561		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected with acute Mycobacterium avium complex infection care	0.561		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected with acute other infection care	0.561		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected with acute Pneumocystis carinii pneumonia infection care	0.607		Patient (n not given)	Torrance transformation of rating scale	

395	HIV-infected with acute fungal infection care	0.652		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected with acute cytomegalovirus infection care	0.652		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected post-acute fungal infection care	0.753		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected post-acute Mycobacterium avium complex infection care	0.772		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected post-acute cytomegalovirus infection care	0.772		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected post-acute toxoplasmosis infection care	0.79		Patient (n not given)	Torrance transformation of rating scale	
395	HIV-infected post-acute Pneumocystis carinii pneumonia infection care	0.807		Patient (n not given)	Torrance transformation of rating scale	
229	persons w/ AIDs	0.4		Expert (not stated who)	Clinical judgement	
231	One major AIDS defining illness (ADI) +minor ADIs	0.4		Patient (69 patients with HIV infection)	Standard gamble	
231	Multiple major AIDS defining illness (ADI)+minor ADIs	0.4		Patient (69 patients with HIV infection)	Standard gamble	
231	Severe side-effects from treatment	0.53		Patient (69 patients with HIV infection)	Standard gamble	
231	One or more minor AIDS defining illness	0.64		Patient (69 patients with HIV infection)	Standard gamble	
241	AIDS	0.53		Author	Author/clinician judgement	
257	Members of the general population with AIDS	0.53		Not stated	Unknown	
329	AIDS	0.77		Community	Rating scale; Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
330	AIDS	0.77		Community	Rating scale Standard gamble	Health Utilities Index (given to 249 Canadian HIV infected patients)
342	AIDS	0.9		Author	Author/clinician judgement	
351	Poor health status with HIV/AIDS	0.2		Author	Author/clinician judgement	
371	Clinical AIDS	0.4		Not stated	Unknown	

389	Other AIDS diagnoses	0.56		Patient (n not given)	Torrance transformation of rating scale	
501	AIDS	0.25	.1-.7	Not stated	Unknown	
514	AIDS	0.17		Clinician (health care workers n not given)	Time trade off	
450	AIDs	0.79		Community	Rating scale	QWB Scale (to 139 patients with HIV)
464	Women with HIV infection & regional or distant cervical cancer	0.56		Patient (n not given)	Torrance transformation of rating scale	
464	Women with HIV infection & local cervical cancer	0.65		Patient (n not given)	Torrance transformation of rating scale	
241	Injection drug user	0.8		Author	Author/clinician judgement	
257	Injection drug uses not in methodone maintenance treatment	0.8		Author	Unknown	
257	Injection drug uses in methodone maintenance treatment	0.9		Author	Unknown	
462	Regional or distant cervical cancer	0.56		Not stated	Unknown	
	Lyme Disease					
462	Localized cervical cancer	0.65		Not stated	Unknown	
282	Meningitis from Lyme disease - 1 month	0.52		Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Myalgias and arthralgias from Lyme disease - 3 days	0.54		Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Radiculoneuritis or cranial neuritis from Lyme disease - 1 month	0.6		Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	

282	"Failure state" - Persistent cognitive difficulty and arthralgias from Lyme disease - 5 years	0.6	Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Cardiac sequelae of Lyme disease - 1 month	0.61	Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Bell Palsy from Lyme disease - 1 month	0.61	Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Arthritic sequelae of Lyme disease - 1 month	0.69	Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
282	Erythema migrans rash (from Lyme disease) - 1 month	0.8	Community (105 residents from Nantucket Island Massachusetts, an area with one of the highest incidences of Lyme disease in the United States)	Rating scale	
527	Rheumatologic sequelae of Lyme disease	0.68	Clinician (expert panel n not given)	Time trade off	
527	Myalgic symptoms of Lyme disease	0.88	Clinician (expert panel n not given)	Time trade off	
527	Oligoarticular arthritis from Lyme disease	0.89	Clinician (expert panel n not given)	Time trade off	
527	Rash resembling erythema migrans	1	Clinician (expert panel n not given)	Time trade off	

527	Utility of treatment, side effects, or cardiac complications of Lyme disease	1		Clinician (expert panel n not given)	Time trade off	
	Measles					
337	Severe disability caused by a case of measles	0.1		Author	Author/clinician judgement	
337	moderate disability caused by a case of measles	0.4		Author	Author/clinician judgement	
337	slight disability caused by a case of measles	0.9		Author	Author/clinician judgement	
	Meningitis					
440	Survivor of acute N meningitidis meningitis with sequel (chronic sequel)	0.62		Community	Standard gamble; Rating scale	Health State Classification System by Torrance done by Authors
440	Year following acute N meningitidis meningitis without sequel	0.95		Community	Standard gamble; Rating scale	Health State Classification System by Torrance done by Authors
440	Routine Vaccine Recipient for N. meningitidis	1		Community	Standard gamble; Rating scale	Health State Classification System by Torrance done by Authors
	Other infectious diseases					
342	Adult T-cell leukemia ATL disease	0.98		Author	Author/clinician judgement	
342	Tropical spastic paraparesis TSP disease	0.98		Author	Author/clinician judgement	
342	Adult T-cell leukemia (ATL) healthy carrier	1		Author	Author/clinician judgement	
342	Adult T-cell leukemia ATL latency	1		Author	Author/clinician judgement	
342	Tropical spastic paraparesis (TSP) healthy carrier	1		Author	Author/clinician judgement	
342	Tropical spastic paraparesis TSP latency	1		Author	Author/clinician judgement	
463	Anal cancer	0.6		Author	Author/clinician judgement	
463	Treatment for anal high-grade squamous intraepithelial lesion (assume a baseline of 1)	0.981		Author	Author/clinician judgement	
535	Vaccine side effect (decrement in days) for Coccidioides immitis	0.1		Author	Author/clinician judgement	
535	Severe disability after meningitis (proxy hemiplegia)	0.27		Author	Author/clinician judgement	

535	Meningeal dissemination (proxy paraplegia)	0.4		Author	Author/clinician judgement	
535	Chronic primary pulmonary infection (proxy pulm TB) from coccidioides immitis	0.57		Author	Author/clinician judgement	
535	Non-meningeal dissemination (proxy orthopedic impairment)	0.59		Author	Author/clinician judgement	
535	Moderate disability after meningitis dissemination (proxy sciatica)	0.69		Author	Author/clinician judgement	
535	Moderate disability after meningitis (proxy sciatica)	0.72		Author	Author/clinician judgement	
535	Diagnosed primary pulmonary infection from coccidioides immitis	0.9		Author	Author/clinician judgement	
535	Chronic azole treatment (proxy warfarin treatment)	0.98		Author	Author/clinician judgement	
535	Well (to compare to pulmonary infection from coccidioides immitis)		.7-.94	Author	Author/clinician judgement	
	2. Neoplasms					
	Liver cancer					
473	Patients with incurable hepatocellular carcinoma and cirrhosis	0.5		Author	Author/clinician judgement	
473	Hepatocellular carcinoma and cirrhosis on the wait list for cadaveric liver transplant	0.6		Author	Author/clinician judgement	
473	Patients with cured hepatocellular carcinoma after cadaveric liver transplant	0.8		Author	Author/clinician judgement	
411	Hepatocellular carcinoma	0.5	.15-.95	Not stated	Unknown	
472	Hepatocellular carcinoma	0.25		Community	Standard gamble □ Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
491	Hepatocellular carcinoma	0.55		Clinician (expert panal of senior hepatologists n not given)	Standard gamble and Time trade off	
495	Hepatocellular carcinoma	0.25		Clinician (expert panal of hepatologists and nurse clinician n not given)	Unknown	
497	Hepatocellular Carcinoma	0.118		Community		Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)

533	Hepatocellular carcinoma	0.25		Author	Unknown	
540	Hepatocellular carcinoma	0.1		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off	
471	Hepatocellular carcinoma	0.2		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
450	Hepatocellular Carunoma	0.49		Clinician (Expert panel n not given)	Standard gamble and Time trade off	
Gastrointestinal cancer						
322	Locally recurrent rectal cancer (patient, HCP as S.A.)	0.72		Patient (25 patients with recurrent rectal cancer)	Standard gamble	
322	Pain & complications caused by locally recurrent rectal cancer or treatment (patient, HCP as S.A.)	0.78		Patient (25 patients with recurrent rectal cancer)	Standard gamble	
322	Surgical resection for locally recurrent rectal cancer (patient, HCP as S.A.)	0.83		Patient (25 patients with recurrent rectal cancer)	Standard gamble	
460	Distant metastatic colorectal cancer	0.25		Clinician	Unknown	
460	Local low rectal cancer (treated with resection, ostomy formation, chemotherapy, and radiation therapy)	0.5		Clinician	Unknown	
460	Regional low rectal cancer	0.5		Clinician	Unknown	
460	Local high rectal cancer (treated with resection, chemotherapy, and radiation therapy)	0.59		Clinician	Unknown	
460	Regional high rectal cancer	0.59		Clinician	Unknown	
460	Regional colon cancer (chemo side effects)	0.63		Clinician	Unknown	
460	Regional colon cancer (no chemo side effects)	0.7		Clinician	Unknown	
460	Local colon cancer	0.74		Clinician	Unknown	
460	Local high rectal cancer (resection only)	0.74		Clinician	Unknown	
460	Local low rectal cancer (resection only)	0.74		Clinician	Unknown	
460	No known adenomas (colorectal)	0.91		Clinician	Unknown	
460	Known adenomas (colorectal)	0.91		Clinician	Unknown	
492	Anal squamous cell cancer, HIV+ with CD4>500	0.56		Patient (n not given)	Torrance transformation of rating scale	
492	Anal squamous cell cancer, HIV+ with CD4 200-500	0.56		Patient (n not given)	Torrance transformation of rating scale	
492	Anal squamous cell cancer, HIV+ with CD4 <200	0.56		Patient (n not given)	Torrance transformation of rating scale	
492	Treatment for high-grade anal squamous intraepithelial lesion (assume a baseline of 1)	0.981		Patient (n not given)	Torrance transformation of rating scale	

525	Resectable stage III colon cancer with treatment-induced toxicity	0.5		Author	Author/clinician judgement	
525	Resectable stage III colon cancer relapse	0.5		Author	Author/clinician judgement	
525	Resectable stage III colon cancer without symptoms and treatment toxicity	1		Author	Author/clinician judgement	
Genitourinary cancers						
434	Incontinence	0.85		Not stated	Unknown	
434	Impotence	0.95		Not stated	Unknown	
469	Prophylactic oophorectomy	0.82		Patient (women with a family history of breast cancer, N not given)	Time trade off	
488	Distant symptomatic disease, hormone resistant (prostate cancer)	0.4		Author/Clinician	Unknown	
488	Distant symptomatic disease, hormone responsive (prostate cancer)	0.8		Author/Clinician	Unknown	
488	Adjustment for living with minor side effect (prostate cancer)	0.85		Author/Clinician	Unknown	
488	Distant asymptomatic disease (prostate cancer)	0.9		Author/Clinician	Unknown	
488	Local recurrent disease in patient with prostate cancer	0.92		Author/Clinician	Unknown	
488	Local bladder outlet obstruction (assume a baseline of 1) (prostate cancer)	0.992		Author/Clinician	Unknown	
488	Severe side effect of treatment of prostate cancer (assume a baseline of 1)	0.992		Author/Clinician	Unknown	
522	Severe neurotoxicity (ovarian cancer)	0.27		Clinician/Patient (10 gynecologic oncologists and 15 females with ovarian cancer who received cisplatin)	Time trade off	
522	Severe nephrotoxicity (ovarian cancer)	0.31		Clinician/Patient (10 gynecologic oncologists and 15 females with ovarian cancer who received cisplatin)	Time trade off	
522	Last 6 months of life (ovarian cancer)	0.4		Clinician/Patient (10 gynecologic oncologists and 15 females with ovarian cancer who received cisplatin)	Time trade off	

522	Mild neurotoxicity (ovarian cancer)	0.62	Clinician/Patient (10 gynecologic oncologists and 15 females with ovarian cancer who received cisplatin)	Time trade off	
522	Mild nephrotoxicity (ovarian cancer)	0.76	Clinician/Patient (10 gynecologic oncologists and 15 females with ovarian cancer who received cisplatin)	Time trade off	
532	Endometrial cancer First year	0.577	Clinician	Unknown	
532	Endometrial cancer Subsequent years	0.881	Clinician	Unknown	
301	Endometrial cancer	0.68	Author	Unknown	
485	Ovarian cancer	0.82	Community (54 participants mean age 38yrs)	Time trade off	
469	Ovarian cancer	0.71	Patient (women with a family history of breast cancer, N not given)	Time trade off	
513	Ovarian cancer	0.82	Author	Author/clinician judgement	
Breast cancer					
278	Advanced breast cancer with Letrozole as second line hormonal therapy: no response and progression during chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.45	Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with Anastrozole as second line hormonal therapy: no response and progression during chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.45	Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with Megestrol Acetate (MA) as second line hormonal therapy: no response and progression during chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.45	Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with Megestrol Acetate (MA) as second line hormonal therapy: no response but response to chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.64	Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with Letrozole as second line hormonal therapy: no response but response to chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.67	Community (25 >18yo Canadian women living in Ontario)	Time trade off	

278	Advanced breast cancer with Anastrozole as second line hormonal therapy: no response but response to chemotherapy (FAC: 5-FU, doxorubicin and cyclophosphamide)	0.67		Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with a response to Letrozole as second line hormonal therapy	0.8		Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with a response to Anastrozole as second line hormonal therapy	0.8		Community (25 >18yo Canadian women living in Ontario)	Time trade off	
278	Advanced breast cancer with a response to Megestrol Acetate (MA) as second line hormonal therapy	0.8		Community (25 >18yo Canadian women living in Ontario)	Time trade off	
301	Metastatic breast cancer	0.52		Patient (women age 33-50 with family history of breast cancer, N not given)	Time trade off	
301	Breast cancer	0.68		Patient (women age 33-50 with family history of breast cancer, N not given)	Time trade off	
362	Breast cancer diagnosed with distant metastases and undergoing treatment	0.7		Author	Author/clinician judgement	
362	Breast cancer diagnosed with distant metastases and in remission after treatme	0.8		Author	Author/clinician judgement	
362	Conservative surgery and radiation therapy for early-stage breast cancer without local or distant recurrence	0.92		Patient/Clinician (97 patients with breast cancer and 20 medical oncology nurses)	Standard gamble	
426	Terminal disease for breast cancer	0.13		Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble	
426	Febrile neutropenia and hospitalised for breast cancer	0.24		Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble	
426	Progressive disease for breast cancer	0.33		Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble	
426	Infection without hospitalisation for breast cancer	0.48		Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble	

426	Severe skin condition with partial/complete response for breast cancer	0.56	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
426	Stable disease for breast cancer	0.62	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
426	Peripheral neuropathy with partial/complete response for breast cancer	0.62	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
426	Start of second-line therapy for breast cancer	0.64	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
426	Severe oedema with partial/complete response for breast cancer	0.78	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
426	Partial/complete response for breast cancer	0.84	Clinician (30 UK oncology nurses and 150 European oncology nurses)	Standard gamble
433	Sick, with no breast cancer	0.5	Not stated	Author/clinician judgement
433	Well after third recurrence of breast cancer	0.55	Not stated	Author/clinician judgement
433	Excisional biopsy (EXB) in patient with suspicious breast lesion (assume a baseline of 1)	1	Not stated	Author/clinician judgement
433	MR imaging in patient with suspicious breast lesion (assume a baseline of 1)	1	Not stated	Author/clinician judgement
433	Core needle biopsy (CNB) in patient with suspicious breast lesion (assume a baseline of 1)	1	Not stated	Author/clinician judgement
433	Well after local or systemic treatment; (assume a baseline of 1)	1	Not stated	Author/clinician judgement
465	Initial surgery for breast cancer (1-2 mos. after treatment)	0.867	Clinician (27 health professionals)	Author/clinician judgement
465	2 mos. - 1 yr. after breast-conserving therapy	0.914	Clinician (27 health professionals)	Author/clinician judgement
465	Disease-free > 1 yr. after breast conserving surgery	0.96	Clinician (27 health professionals)	Author/clinician judgement
466	Metastatic breast cancer with terminal disease following chemotherapy	0.23	Clinician (29 US oncology nurses)	Standard gamble
466	Metastatic breast cancer with stable disease and peripheral neuropathy following chemotherapy	0.41	Clinician (29 US oncology nurses)	Standard gamble
466	Metastatic breast cancer with febrile neutropenia requiring hospitalization following chemotherapy	0.42	Clinician (29 US oncology nurses)	Standard gamble

466	Metastatic breast cancer with progressive disease following chemotherapy	0.49		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with cardiac toxicity following chemotherapy	0.54		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with infection but no hospitalization following chemotherapy	0.56		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with partial/full response to chemotherapy and peripheral neuropathy	0.58		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with severe skin condition following chemotherapy	0.65		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with stable disease and severe edema following chemotherapy	0.68		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer at start of second-line chemotherapy	0.69		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with stable disease following chemotherapy	0.7		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with partial/full response to chemotherapy and severe edema	0.82		Clinician (29 US oncology nurses)	Standard gamble	
466	Metastatic breast cancer with partial/full response to chemotherapy	0.84		Clinician (29 US oncology nurses)	Standard gamble	
469	Metastatic cancer	0.59		Patient (women with a family history of breast cancer, N not given)	Time trade off	
469	Genetic risk	0.76		Patient (women with a family history of breast cancer, N not given)	Time trade off	
469	Breast cancer	0.83		Patient (women with a family history of breast cancer, N not given)	Time trade off	
476	Alive with breast cancer	0.7		Author	Author/clinician judgement	
476	Alive with breast cancer undergoing or soon following Radiation therapy (3 months)	0.9		Author	Author/clinician judgement	
478	Pre-menopausal node-positive breast cancer patient following locoregional radiotherapy	0.9		Not stated	Unknown	
481	Hypercalcemia in setting of breast CA mets to bone	0.2		Author	Author/clinician judgement	
481	No therapy and no skeletal-related events (in setting of metastatic breast CA)	1		Author	Author/clinician judgement	
483	Diagnosed with distant metastases and undergoing salvage chemotherapy	0.7		Author	Author/clinical judgement	
483	In remission with distant metastases	0.75		Author	Author/clinical judgement	
485	Metastatic disease	0.63		Community (54 participants mean age 38yrs)	Time trade off	

485	Breast cancer	0.89	Community (54 participants mean age 38yrs)	Time trade off	
499	Third recurrence	0.3	Clinician	Author/clinician judgement	
499	Second recurrence	0.5	Clinician	Author/clinician judgement	
499	First recurrence	0.7	Clinician	Author/clinician judgement	
499	Second remission	0.7	Clinician	Author/clinician judgement	
499	First remission	0.85	Clinician	Author/clinician judgement	
499	Well, no evidence of recurrence	1	Clinician	Author/clinician judgement	
513	Breast and ovarian cancer	0.82	Author	Author/clinician judgement	
513	Breast cancer	0.89	Author	Author/clinician judgement	
532	Breast cancer Subsequent years	0.864	Clinician	Unknown	
532	Breast cancer First year	0.546	Clinician	Unknown	
	Breast cancer treatments				
469	Prophylactic mastectomy	0.76	Patient (women with a family history of breast cancer, N not given)	Time trade off	
469	Chemoprevention	0.81	Patient (women with a family history of breast cancer, N not given)	Time trade off	
513	Oophorectomy before age 50 with hormone replacement	0.91	Author	Author/clinician judgement	
513	Oophorectomy before age 50 with no hormone replacement	1	Author	Author/clinician judgement	
513	Mastectomy	0.86	Author	Author/clinician judgement	
513	Mastectomy and oophorectomy	0.86	Author	Author/clinician judgement	
499	Chemotherapy-fetal toxicity	0	Clinician	Author/clinician judgement	
499	Chemotherapy-major toxicity	0.8	Clinician	Author/clinician judgement	
499	Chemotherapy- minor toxicity	0.9	Clinician	Author/clinician judgement	
499	Axillary lymph node dissection	0.95	Clinician	Author/clinician judgement	
499	Tamoxifen treatment	0.98	Clinician	Author/clinician judgement	

485	Prophylactic oophorectomy	0.91		Community (54 participants mean age 38yrs)	Time trade off	
485	Prophylactic oophorectomy and mastectomy	0.86		Community (54 participants mean age 38yrs)	Time trade off	
483	Treatment with or without electron-beam boost with local recurrence salvaged by mastectomy and reconstructive surgery	0.82		Patient (97 breast cancer patients)	Standard gamble	
483	Treatment with or without electron-beam boost without evidence of recurrence in patient with breast cancer	0.92		Patient (97 breast cancer patients)	Standard gamble	
482	Docetaxel treatment in patient with breast cancer: Toxicity from treatment	0.1		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Paclitaxel treatment in patient with breast cancer: Toxicity from treatment	0.12		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Docetaxel treatment in patient with breast cancer: No response to treatment	0.17		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Vinorelbine treatment in patient with breast cancer: Toxicity from treatment	0.23		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Paclitaxel treatment in patient with breast cancer: No response to treatment	0.24		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Vinorelbine treatment in patient with breast cancer: No response to treatment	0.41		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Docetaxel treatment in patient with breast cancer: Response to treatment	0.51		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	

482	Paclitaxel treatment in patient with breast cancer: Response to treatment	0.62		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
482	Vinorelbine treatment in patient with breast cancer: Response to treatment	0.8		Community/Patients (25 healthy volunteers and 25 breast cancer patients in Canada)	Time trade off	
481	Pamidronate therapy and no skeletal-related events (in setting of met breast CA)	1		Author	Author/clinician judgement	
476	Severe radiation therapy-induced toxicity in patient with breast cancer	0.8		Author	Author/clinician judgement	
469	Both surgeries (oophorectomy and mastectomy)	0.73		Patient (women with a family history of breast cancer, N not given)	Time trade off	
240	during therapy with CMF (cydophosphamide, methotrexate, fluorouracil) (6 months)	0.67		Author	Author/clinician judgement	
240	Following adjuvant CMF(cydophosphamide, methotrexate, fluorouracil) lasting for rest of life	0.86		Author	Author/clinician judgement	
301	Chemoprevention	0.79		Patient (women age 33-50 with family history of breast cancer, N not given)	Time trade off	
465	Secondary therapy & CMF 6 mos. for local breast cancer recurrence (2 mos.- 8mos. after surgery and/or radiotherapy for local recurrence)	0.502		Clinician (8 health professionals)	Author/clinician judgement	
465	Secondary therapy & TAM 2 yrs. for local breast cancer recurrence (2 mos.- 2 yrs. after surgery and/or radiotherapy for local recurrence)	0.578		Clinician (8 health professionals)	Author/clinician judgement	
465	Mastectomy and radiotherapy for local breast cancer recurrence (0-2 mos. after surgery + radiotherapy)	0.587		Clinician (8 health professionals)	Author/clinician judgement	
465	Mastectomy for local breast cancer recurrence (0-2 mos. after surgery)	0.6		Clinician (8 health professionals)	Author/clinician judgement	
465	New sector resection & radiotherapy for local breast cancer recurrence (0-2 mos. after surgery + radiotherapy)	0.68		Clinician (8 health professionals)	Author/clinician judgement	
465	New sector resection for local breast cancer recurrence (0-2 mos. after surgery)	0.73		Clinician (8 health professionals)	Author/clinician judgement	
465	Initial radiotherapy for breast cancer (0-2 mos. after surgery + radiotherapy)	0.803		Clinician (27 health professionals)	Author/clinician judgement	
433	Chemo with major side effects and tamoxifen (assume a baseline of 1)	0.79		Not stated	Author/clinician judgement	
433	Chemotherapy with major side effects (assume a baseline of 1)	0.8		Not stated	Author/clinician judgement	
433	Chemo with minor side effects and tamoxifen (assume a baseline of 1)	0.89		Not stated	Author/clinician judgement	

433	Chemo with minor side effects (assume a baseline of 1)	0.9		Not stated	Author/clinician judgement	
433	Tamoxifen treatment (assume a baseline of 1)	0.99		Not stated	Author/clinician judgement	
362	Conservative surgery alone for early-stage breast cancer with an isolated local recurrence salvaged with mastectomy and reconstructive surgery	0.81		Patient/Clinician (97 patients with breast cancer and 20 medical oncology nurses)	Standard gamble	
362	Conservative surgery and radiation therapy for early-stage breast cancer with an isolated local recurrence salvaged with mastectomy and reconstructive surgery	0.82		Patient/Clinician (97 patients with breast cancer and 20 medical oncology nurses)	Standard gamble	
362	Conservative surgery alone for early-stage breast cancer with an isolated local recurrence salvaged with further conservative surgery and radiation therapy	0.87		Patient/Clinician (97 patients with breast cancer and 20 medical oncology nurses)	Standard gamble	
362	Conservative surgery alone for early-stage breast cancer without local or distant recurrence	0.88		Patient/Clinician (97 patients with breast cancer and 20 medical oncology nurses)	Standard gamble	
Cancer treatment						
468	Patients treated with any chemotherapy	0.47		Patient (N not given)	Rating scale	
468	Patients treated with cisplatin-containing chemotherapy	0.5		Patient (N not given)	Rating scale	
468	Hepatocellular carcinoma	0.5		Patient (N not given)	Rating scale	
468	Patients treated with any chemotherapy after anemia correction with rHuEPO	0.61		Patient (N not given)	Rating scale	
468	Patients treated with cisplatin-containing chemotherapy after anemia correction with rHuEPO	0.74		Patient (N not given)	Rating scale	
468	Chirrosis	0.8		Patient (N not given)	Rating scale	
468	Chronic active hepatitis	0.94		Patient (N not given)	Rating scale	
Lung cancer						
489	vinblastine + cisplatin	0.52		Clinician (24 oncologists)	Rating scale	
489	Best supportive care for patient with metastatic non-small cell lung cancer	0.53		Clinician (24 oncologists)	Rating scale	
489	etoposide + cisplatin	0.55		Clinician (24 oncologists)	Rating scale	

489	vinorelbine (Navelbine)	0.6	Clinician (24 oncologists)	Rating scale	
489	vinorelbine + cisplatin	0.6	Clinician (24 oncologists)	Rating scale	
489	paclitaxel + cisplatin, 135 mg/m ²	0.63	Clinician (24 oncologists)	Rating scale	
489	paclitaxel + cisplatin, 200 mg/m ²	0.63	Clinician (24 oncologists)	Rating scale	
489	paclitaxel + cisplatin, 250 mg/m ²	0.63	Clinician (24 oncologists)	Rating scale	
489	gemcitabine	0.65	Clinician (24 oncologists)	Rating scale	
	Leukemia				
467	Life with chronic Graft-Versus-Host-Disease (status post allogeneic bone marrow transplant) (Chronic Myelogenous Leukemia)	0.9	Clinician (N not given)	Standard gamble	
467	Life without chronic Graft-Versus-Host-Disease (status post allogeneic bone marrow transplant) (Chronic Myelogenous Leukemia)	0.979	Clinician (N not given)	Standard gamble	
494	Toxicity (therapy is discontinued in following month) (Chronic Myelogenous Leukemia)	0	Not stated	Unknown	
494	Progressive disease (Chronic Myelogenous Leukemia)	0.5	Not stated	Unknown	
494	Interferon (Chronic Myelogenous Leukemia)	0.9	Not stated	Unknown	
494	Chemotherapy (Chronic Myelogenous Leukemia)	1	Not stated	Unknown	
494	Cytarabine (Chronic Myelogenous Leukemia)	1	Not stated	Unknown	
	Lymphoma				
477	Combined modality therapy in early stage hodgkin's disease for 8.4 months	0.5	Author	Author/clinician judgement	
477	Chemotherapy in early stage hodgkin's disease for 6 months	0.7	Author	Author/clinician judgement	
477	Mantle and Para Aortic Radiation in early stage hodgkin's disease for 2.4 months	0.7	Author	Author/clinician judgement	
477	Mantle radiotherapy in early stage hodgkin's disease for 1.2 months	0.9	Author	Author/clinician judgement	
477	Transplant in early stage hodgkin's disease (assume a baseline of 1)	0.9	Author	Author/clinician judgement	
477	Refractory disease state in patient with early stage hodgkin's disease	0.98	Author	Author/clinician judgement	
477	Secondary malignancies state in patient with early stage hodgkin's disease	0.98	Author	Author/clinician judgement	
477	Post Laparotomy state in patient with early stage hodgkin's disease	0.99	Author	Author/clinician judgement	
477	Relapse State in patient with early stage hodgkin's disease	0.99	Author	Author/clinician judgement	
477	Laparotomy in early stage hodgkin's disease (assume a baseline of 1)	0.995	Author	Author/clinician judgement	

477	Remission State for patient with early stage hodgkin's disease	1		Author	Author/clinician judgement	
493	Progressive Disease (Non-Hodgkin's Lymphoma)	0.7		Clinician (three panels of experts N not given)	Unknown	
493	On IFN (Non-Hodgkin's Lymphoma)	0.93		Clinician (three panels of experts N not given)	Unknown	
493	On chemo only (Non-Hodgkin's Lymphoma)	1		Clinician (three panels of experts N not given)	Unknown	
	Melanoma					
504	Stage II melanoma (assumes a baseline of 1)	0.419		Clinician (panel of 4 clinicians)	Rating scale	
504	Stage III melanoma (assumes a baseline of 1)	0.425		Clinician (panel of 4 clinicians)	Rating scale	
504	Stage IV melanoma (assumes a baseline of 1)	0.513		Clinician (panel of 4 clinicians)	Rating scale	
504	Stage I melanoma (assumes a baseline of 1)	0.65		Clinician (panel of 4 clinicians)	Rating scale	
504	Nonmelanoma skin cancer (assumes a baseline of 1)	0.973		Clinician (panel of 4 clinicians)	Rating scale	
504	Biopsy for malignant melanoma (assumes a baseline of 1)	0.9989		Clinician (panel of 4 clinicians)	Rating scale	
504	Screen for malignant melanoma	1		Clinician (panel of 4 clinicians)	Rating scale	
508	Time in relapse (Malignant melanoma)	0.5		Author	Author/clinician judgement	
508	Time with adverse events from IFN alpha-2a (Malignant melanoma)	0.8		Author	Author/clinician judgement	
508	Time without symptoms or toxicity (Malignant melanoma treatment with interferon alpha-2a)	1		Author	Author/clinician judgement	
	Other					
496	Medulloblastoma tumor - Metastatic	0.31		Community	Standard gamble; Rating scale	The Health Utilities Index (used by physician)
496	Nonmedulloblastoma tumors - Residual tumor	0.51		Community	Standard gamble; Rating scale	The Health Utilities Index (used by physician)
496	Medulloblastoma tumor - Nonmetastetic	0.76		Community	Standard gamble; Rating scale	The Health Utilities Index (used by physician)

496	Nonmedulloblastoma tumors - No residual tumor	0.93	Community	Standard gamble; Rating scale	The Health Utilities Index (used by physician)
537	Radiation plus radical neck dissection for N0 HNSCC	0.675	Clinician (8 surveys)	Time trade off	
537	Radical neck dissection for N0 HNSCC	0.763	Clinician (8 surveys)	Time trade off	
537	Radiation for N0 HNSCC	0.875	Clinician (8 surveys)	Time trade off	
537	Radiation plus modified neck dissection for N0 HNSCC	0.913	Clinician (8 surveys)	Time trade off	
537	Modified neck dissection for classification N0 head and neck squamous cell carcinoma (HNSCC)	0.925	Clinician (8 surveys)	Time trade off	
	Thyroid				
382	Undiagnosed, symptomatic postpartum thyroiditis	0.81	Not stated	Unknown	
382	Symptomatic postpartum thyroiditis, incorrectly diagnosed as depression	0.81	Not stated	Unknown	
382	Diagnosed, symptomatic postpartum thyroiditis	0.89	Not stated	Unknown	
382	Graves' disease	0.94	Not stated	Unknown	
382	Asymptomatic postpartum thyroiditis	1	Not stated	Unknown	
424	Myxedema	0.4	Not stated	Unknown	
424	CHD	0.6	Not stated	Unknown	
424	Overt hypothyroidism	0.74	Not stated	Unknown	
424	Subclinical hypothyroidism	0.9	Not stated	Unknown	
424	Euthyroid	1	Not stated	Unknown	
	Diabetes				
244	Diabetes	0.9	Not stated	Unknown	
246	Angiotensin-converting enzyme (ACE) inhibition	0.826	Not stated	Unknown	
246	Insulin-dependent diabetes mellitus	0.838	Not stated	Unknown	
247	Dialysis-dependent, insulin-dependent diabetic following SPK transplantation	0.4	Patient (17 simultaneous pancreas-kidney transplant patients)	Standard gamble	
247	Dialysis-dependent, insulin-free diabetic following SPK transplantation	0.5	Patient (17 simultaneous pancreas-kidney transplant patients)	Standard gamble	
247	Dialysis-free, insulin-dependent diabetic following SPK transplantation	0.6	Patient (17 simultaneous pancreas-kidney transplant patients)	Standard gamble	

247	Dialysis-free, insulin-free diabetic following SPK transplantation	1		Patient (17 simultaneous pancreas-kidney trnasplant patients)	Standard gamble	
273	Diabetes	0.76		Community	Rating scale □ Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
273	ACE Inhibitor	1		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
318	Foveal photocoagulation - complication of grid photocoagulation for diabetic macular edema	0.3		Author	Author/Cinical judgement	
318	Rupture of Bruch's membrane - complication of grid photocoagulation for diabetic macular edema	0.5		Author	Author/Cinical judgement	
318	Retinal vascular occlusion - complication of grid photocoagulation for diabetic macular edema	0.6		Author	Author/Cinical judgement	
318	Viisual acuity doubled in 3 years (initial <20/60) in setting of diabetic retinopathy with macular edema	0.59		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity doubled in 3 years (initial 20/50-20/60) in setting of diabetic retinopathy with macular edema	0.72		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity not doubled in 3 years (initial <20/60) in setting of diabetic retinopathy with macular edema	0.72		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity doubled in 3 years (initial 20/20-20/25) in setting of diabetic retinopathy with macular edema	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity not doubled in 3 years (initial 20/30-20/40) in setting of diabetic retinopathy with macular edema	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity doubled in 3 years (initial 20/30-20/40) in setting of diabetic retinopathy with macular edema	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity not doubled in 3 years (initial 20/50-20/60) in setting of diabetic retinopathy with macular edema	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity doubled in 3 years (initial >20/20) in setting of diabetic retinopathy with macular edema	0.8		Patient (100 patients with diabetic retinopathy)	Time trade off	
318	Viisual acuity not doubled in 3 years (initial 20/20-20/25) in setting of diabetic retinopathy with macular edema	0.85		Patient (100 patients with diabetic retinopathy)	Time trade off	

318	Viisual acuity not doubled in 3 years (initial >20/20) in setting of diabetic retinopathy with macular edema	1		Patient (100 patients with diabetic retinopathy)	Time trade off	
319	G5 (Count fingers to hand motion) in better seeing eye in setting of diabetic retinopathy with vitreous hemorrhage	0.59		Patient (100 patients with diabetic retinopathy)	Time trade off	
319	G4 (20/200-20/400) in better seeing eye in setting of diabetic retinopathy with vitreous hemorrhage	0.64		Patient (100 patients with diabetic retinopathy)	Time trade off	
319	G2 (20/30-20/50) in better seeing eye in setting of diabetic retinopathy with vitreous hemorrhage	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
319	G3 (20/60-20/100) in better seeing eye in setting of diabetic retinopathy with vitreous hemorrhage	0.78		Patient (100 patients with diabetic retinopathy)	Time trade off	
319	G1 (20/25 or better) in better seeing eye in setting of diabetic retinopathy with vitreous hemorrhage	0.85		Patient (100 patients with diabetic retinopathy)	Time trade off	
320	End Stage Renal Disease and Type II Diabetes	0.61		Not stated	Unknown	
320	Blindness and Type II Diabetes	0.69		Not stated	Unknown	
320	Lower Extremity Amputation and Type II Diabetes	0.8		Not stated	Unknown	
320	Screen - detected Type II Diabetes	0.95		Not stated	Unknown	
320	Life with Diabetes, no complication	0.95		Not stated	Unknown	
321	DM with After healing with major amputation	0.31		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (notstated to whom it was given)
321	DM with Ongoing ulcer	0.44		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (notstated to whom it was given)
321	DM with After primary healing of foot ulcer	0.6		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (notstated to whom it was given)
321	DM with After healing with minor amputation	0.61		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (notstated to whom it was given)
321	DM with No foot ulcer	0.8		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
382	IDDM & Undiagnosed, symptomatic postpartum thyroiditis	0.68		Not stated	Unknown	

382	IDDM & Symptomatic postpartum thyroiditis, incorrectly diagnosed as depression	0.68		Not stated	Unknown	
382	IDDM & Diagnosed, symptomatic postpartum thyroiditis	0.75		Not stated	Unknown	
382	IDDM & Graves' disease	0.79		Not stated	Unknown	
382	IDDM	0.84		Not stated	Unknown	
382	IDDM & Asymptomatic postpartum thyroiditis	0.84		Not stated	Unknown	
384	Blindness	0.69		Author	Author/Clinical Judgement	
451	Type 1 diabetic patient with both dialysis and blindness	0.4		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient with blindness	0.48		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient with blindness and kidney transplant	0.49		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient on dialysis	0.57		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient with functioning kidney transplant	0.72		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient requiring insulin injections alone	0.75		Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	

451	Type 1 diabetic patient with functioning pancreas transplant	0.95	Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
451	Type 1 diabetic patient with functioning pancreas kidney transplant	0.95	Patient (16 patients 10/6 male/femal all <48 yo with type 1 diabetes mellitus and end stage renal disease)	Standard gamble	
523	Diabetic state	0.82	Patient (9385 patients)	Unknown	
Sex Hormones					
295	Woman with severe menopausal symptoms	0.64	Author	Author/Cinical judfement	
295	Woman with mild menopausal symptoms	0.85	Author	Author/Cinical judfement	
Other Endocrine					
480	Incidental microadenoma (1st 2 yrs.)	0.99	Not stated	Unknown	
480	No endocrinopathies or neurological deficits in patient with incidental pituitary microademomas	1	Not stated	Unknown	
480	Hyperprolactinemia	1	Not stated	Unknown	
480	Cushing's syndrome	1	Not stated	Unknown	
480	Acromegaly	1	Not stated	Unknown	
480	Bromocriptine treatment	1	Not stated	Unknown	
480	Incidental microadenoma (after 2 yrs.)	1	Not stated	Unknown	
4. Diseases of the Blood and Blood-Forming Organs					
Hematology - Other					
331	Haemophilia pateints during the 6 months preceding the introduction of rFVIIa treatemnt	-0.11	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to 50 patients and their parents with haemophilia
331	Haemophilia pateints during the 6 months on rFVIIa treatment assessed retrospectively	0.46	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to 50 patients and their parents with haemophilia

331	Haemophilia patients during the 6 months on rFVIIa treatment assessed prospectively	0.48	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to 50 patients and their parents with haemophilia
5. Mental Disorders					
Depression					
268	Major Depression	0.63	Author	Author/clinician judgement	
268	Significant Depressive Symptoms	0.70	Author	Author/clinician judgement	
268	Depression in full remission	0.89	Author	Author/clinical judgement	
268	Patients with major depression or significant depressive symptoms on antidepressant medication (assume baseline of 1)	0.99	Author	Author/clinical judgement	
268	Patients in remission on antidepressant medication (assume baseline of 1)	0.98	Author	Author/clinical judgement	
281	Major Depression	.59	Author	Author/clinical judgement	
388	Year with depression	0.7	Community	SF-36/12, transformed	SF-36/12, transformed (Given to primary care patients with depression N not given)
457	Depression treated with selective serotonin reuptake inhibitor (SSRI)	0.7	Author	Author/clinical judgement	
457	Depression treated with tricyclic antidepressant (TCA)	0.64	Author	Author/clinical judgement	
457	Depression in remission on prolonged treatment with a selective serotonin reuptake inhibitor (SSRI)	0.8	Author	Author/clinical judgement	
457	Depression in remission on prolonged treatment with a tricyclic antidepressant (TCA)	0.72	Author	Author/clinical judgement	
457	Depression in remission - off of drug therapy	0.86	Author	Author/clinical judgement	
457	Severe depression	0.3	Author	Author/clinical judgement	
Schizophrenia					

530	Schizophrenia patients	0.73	.69-.97	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 200 schizophrenic outpatients from the Outpatients Clinic Slovenia who were receiving depot neuroleptics)
Anxiety Disorder						
511	Panic disorder, in remission	0.86		Patient	Unknown	
511	Panic disorder, symptomatic	0.4		Patient	Unknown	
511	Panic disorder, responding to imiprimine therapy (end of week 8)	0.55		Patient	Unknown	
511	Panic disorder, responding to imiprimine therapy (end of week 16)	0.705		Patient	Unknown	
511	Panic disorder, responding to imiprimine therapy (end of week 24)	0.86		Patient	Unknown	
511	Panic disorder, nonresponder/withdrawal to imiprimine therapy (end of week 8)	0.425		Patient	Unknown	
511	Panic disorder, nonresponder/withdrawal to imiprimine therapy (end of week 16)	0.5		Patient	Unknown	
511	Panic disorder, nonresponder/withdrawal to imiprimine therapy (end of week 24)	0.575		Patient	Unknown	
511	Panic disorder, nonresponder/withdrawal to imiprimine therapy (after week 24)	0.65		Patient	Unknown	
Substance Abuse						
241	In maintenance treatment	0.90		Author	Author/clinician judgement	
241	Injection drug user	0.80		Author	Author/clinician judgement	
257	Uninfected members of the general population	1.00		Not stated	Unknown	
257	Asymptomatic non-injection drug users who are HIV infected	0.90		Not stated	Unknown	
257	Members of the general population with AIDS	0.53		Not stated	Unknown	
257	Injection drug uses not in methodone maintenance treatment	0.80		Author	Author/clinical judgement	
257	Injection drug uses in methodone maintenance treatment	0.90		Author	Author/clinical judgement	
427	Before treatment with methylphenidate in children with hyperactivity - PID2E3 (Health related quality of life with no pain, slight social disability, moderate emotional distress)	0.884		Community	Standard gamble; Rating scale	Index of Health Related Quality of Life (used by author)

427	After Treatment with methylphenidate in children with hyperactivity - P1D1E2 (Health related quality of life with no pain, no physical or social disability, slight emotional distress)	0.97		Community	Standard gamble; Rating scale	Index of Health Related Quality of Life (used by author)
354	Intensive care admission with diagnosis Intoxication (6 mo post discharge)	0.71		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
6. Diseases of the Nervous System and Sense Organs						
Eyes						
407	Patient presenting with 20/200 vision (base case 2) Develops 3-line visual loss	0.4		Patient (80 patients with age-related macular degeneration)	Time trade off	
407	Patient presenting with 20/200 vision (base case 2 and does not develop 3-line visual loss	0.52		Patient (80 patients with age-related macular degeneration)	Time trade off	
407	Patient presenting with 20/40 vision (base case 1) Does not develop 3-line visual loss	0.81		Patient (80 patients with age-related macular degeneration)	Time trade off	
407	Patient presenting with 20/40 vision (base case 1) and Develops 3-line visual loss	0.57		Patient (80 patients with age-related macular degeneration)	Time trade off	
301	Cataract surgery	0.68		Patient (47 patients awaiting cataract surgery)	Rating Scale	
408	Subfoveal choroidal neovascularization with visual acuity in better eye of 20/500	0.53		Patient (325 patients with visual loss)	Unknown	
408	Subfoveal choroidal neovascularization with visual acuity in better eye of 20/400	0.54		Patient (325 patients with visual loss)	Unknown	
408	Subfoveal choroidal neovascularization with visual acuity in better eye of 20/320	0.61		Patient (325 patients with visual loss)	Unknown	
408	Subfoveal choroidal neovascularization with visual acuity in better eye of 20/200	0.66		Patient (325 patients with visual loss)	Unknown	
408	Subfoveal choroidal neovascularization with visual acuity in better eye of 20/40	0.8		Patient (325 patients with visual loss)	Unknown	
412	Retinopathy of prematurity: Threshold retinopathy group	0.6		Patient (n not given)	Multivariate regression analysis	

412	Retinopathy of prematurity: Cryotherapy group	0.63		Patient (n not given)	Multivariate regression analysis	
412	Retinopathy of prematurity: Laser treated group	0.7		Patient (n not given)	Multivariate regression analysis	
438	Choroidal neovascularization with visual acuity of 20/70 in unaffected eye	0.71		Patient (325 patients with visual loss of $\geq 20/40$ in at least 1 eye)	Rating Scale	
438	Choroidal neovascularization with visual acuity of 20/40 in unaffected eye	0.8		Patient (325 patients with visual loss of $\geq 20/40$ in at least 1 eye)	Rating Scale	
438	Choroidal neovascularization with visual acuity of 20/20 or 20/25 in unaffected eye	0.9		Patient (325 patients with visual loss of $\geq 20/40$ in at least 1 eye)	Rating Scale	
Ears and Hearing						
391	Improvement from cochlear implantation	0.23		Not stated	Unknown	
385	Profoundly deaf child	0.25		Community	Rating scale; Time trade off; Standard gamble	Health Utilities Index (parents of deaf children n=22) VAS n=78 and TTO n=40
350	Child following cochlear implantation (improvement in QoL)	0.2571		Community	Author/clinician judgement; Magnitude estimation; Rating scale	HRQOL-15D (given to two clinicians)
287	Severe to profound deafness	0.58		Community	Rating scale; Standard gamble	Health Utilities Index (given to 62 adult patients with profound hearing impairment)
385	Child after cochlear implantation for profound deafness	0.64		Community	Rating scale; Time trade off; Standard gamble	Health Utilities Index (parents of deaf children n=22) VAS n=78 and TTO n=40

287	12 months after cochlear implant for severe to profound deafness	0.78		Community	Rating scale; Standard gamble	Health Utilities Index (given to 62 adult patients with profound hearing impairment)
Dementia						
400	Severe Alzheimer's disease - living in nursing home	0.31		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Severe Alzheimer's disease, living in nursing home	0.31		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)
400	Severe Alzheimer's disease - living in community	0.37		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Severe Alzheimer's disease, living in community	0.37		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)

400	Moderate Alzheimer's disease - living in nursing home	0.48		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Moderate Alzheimer's disease, living in nursing home	0.48		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)
400	Moderate Alzheimer's disease - living in community	0.54		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Moderate Alzheimer's disease, living in community	0.54		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)

400	Mild Alzheimer's disease - living in community	0.68		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Mild Alzheimer's disease, living in community	0.68		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)
400	Mild Alzheimer's disease - living in nursing home	0.71		Community	Rating scale; Standard gamble	Health Utilities Index given to 528 caregivers of AD patients, stratified by CDR disease stage (201 mild, 175 moderate, and 142 severe) and setting of care (354 community and 164 nursing home)
436	Mild Alzheimer's disease, living in nursing home	0.71		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)
436	No Alzheimer's disease	0.826		Community	Standard gamble; Rating scale	Health Utilities Index (given to patients n not given)
Multiple Sclerosis						
293	Postal Ambulation scale score (6) Restricted to bed	-0.26		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=6)

479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 7	-0.027		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
293	Postal Ambulation scale score (5) wheelchair dependent	0.015		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=46)
479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 6	0.21		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 5	0.333		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
414	Expanded Disability Status Score in pt with Multiple sclerosis 7	0.35		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients n not given
490	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 7	0.35		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
490	Severe disease in patient with multiple sclerosis	0.359		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
293	Postal Ambulation scale score (4) walk indoors with assistance	0.389		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=20)
414	Expanded Disability Status Score in pt with Multiple sclerosis 6	0.49		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients n not given
490	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 6	0.49		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)

479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 4	0.496		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
414	Expanded Disability Status Score in pt with Multiple sclerosis 5	0.52		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients n not given
490	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 5	0.52		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 2	0.534		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 3	0.544		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
293	Postal Ambulation scale score (2) up to 500 m unaided	0.62		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=1)
293	Postal Ambulation scale score (3) up to 250 m with aid	0.643		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=9)
414	Expanded Disability Status Score in pt with Multiple sclerosis 4	0.66		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients n not given
490	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 4	0.66		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
479	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 1	0.677		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)

414	Expanded Disability Status Score in pt with Multiple sclerosis 3	0.71		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients n not given
490	Expanded Disability Status Scale Scores in patients with Multiple Sclerosis 3	0.71		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
490	Placebo in patient with multiple sclerosis	0.856		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
490	IF beta-1b in patient with multiple sclerosis	0.87		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 96 patients with MS)
479	relapse (utility loss) (assume a baseline of 1)	0.9365		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 413 patients with MS)
293	Postal Ambulation scale score (1) unrestricted	1		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients n=2)
	Other					
413	ALS with inability to speak, gastrostomy, respiratory function severely impaired with tracheostomy, fully dependent on caregiver for transfers/dressing/feeding, quadriplegic, not working and most likely in a long-term care facility, medical care for pain.	-0.53		Clinician (10 member panel)	Standard gamble	
413	ALS with speech intelligible less than 25% of time and requires a device to communicate, diet limited to pureed/blended/thick liquids and likely needs tube feedings, breathing impaired to extent that pressure support (CPAP or BIPAP) and home oxygen may be required, fully dependent on caregiver for transfers/dressing/feeding, wheelchair-bound, not working, medical care has extended to consultations for tracheostomy and gastrostomy, and pain medications.	0.01		Clinician (10 member panel)	Standard gamble	

413	ALS with speech intelligible less than 50% of time, diet limited to food of pudding consistency, breathing impaired to point at increased risk for infection, requires caretaker to assist with transfers/dressing/feeding, requires use of wheelchair much of the time, most likely has stopped working, medical care has extended to PEG consultations, pain medications, and unexpected hospitalizations.	0.41		Clinician (10 member panel)	Standard gamble	
368	ALS severity level 4 (terminal)	0.45		Patient (n=77 with different levels of disease severity from two centers in the UK)	Standard gamble	
368	ALS severity level 2 (mod)	0.67		Patient (n=77 with different levels of disease severity from two centers in the UK)	Standard gamble	
368	ALS severity level 3 (severe)	0.71		Patient (n=77 with different levels of disease severity from two centers in the UK)	Standard gamble	
368	ALS severity level 1 (mild)	0.79		Patient (n=77 with different levels of disease severity from two centers in the UK)	Standard gamble	
367	ALS/MND survival after riluzole therapy	0.8		Author	Author/clinician judgement	
413	ALS with speech intelligible at least 75% of time, diet limited to finely chopped or ground foods andd thick liquids, breathing moderately impaired with dyspnea on exertion but effective cough, minimal care required for dressing and feeding, mobility aids such as crutches or occassional wheelchair needed, work limited to part time, medical preocedures include chest physiotherapy and diagnostic spirometry	0.82		Clinician (10 member panel)	Standard gamble	
413	ALS with normal to slightly slurred speech, diet with hard foods that are difficult to swallow eliminated, normal breathing, dress/feed/live independently, able to work full time, medical preocedures only diagnostic	0.89		Clinician (10 member panel)	Standard gamble	
401	Assumes Parkinson Disease patient Quality of life declines exponetially w/ age after age 55 to 0.4 by age 95 in those not receiving Deep brain stimulation (DBS): 95 yr old with advanced Parkinson Disease	0.4		Author	Author/clinician judgement	
422	Parkinsons' HY Stage 5	0.451		Patient (n=470 with Parkinsons disease)	Time trade off	

422	Parkinsons' HY Stage 4	0.547	Patient (n=470 with Parkinsons disease)	Time trade off	
401	55 yr old w/ advanced Parkinson Disease	0.55	Author	Author/clinician judgement	
422	Parkinsons' HY Stage 3	0.622	Patient (n=470 with Parkinsons disease)	Time trade off	
456	Patient with Parkinson's Disease > 25% off time/ day (off time corresponds with the percentage of time awake that the patient experiences abnormal involuntary movements)	0.65	Patient (n not given)	Standard gamble	
422	Parkinsons' HY Stage 2	0.678	Patient (n=470 with Parkinsons disease)	Time trade off	
422	Parkinsons' HY Stage 1	0.708	Patient (n=470 with Parkinsons disease)	Time trade off	
422	Parkinsons' Hoehn-Yahr (HY) Stage 0	0.719	Patient (n=470 with Parkinsons disease)	Time trade off	
401	Deep Brain Stimulation in Parkinsons patient	0.72	Author	Author/clinician judgement	
456	Patient with Parkinson's Disease <= 25% off time/ day (off time corresponds with the percentage of time awake that the patient experiences abnormal involuntary movements)	0.79	Patient (n not given)	Standard gamble	
Seizures					
325	Refractory seizures and drug-related side effects of Lamotrigine	0.4	Patient (n=81 with refractory seizures)	Time trade off	
325	Suboptimal seizure control (>=10 seizures/month) on lamotrigine	0.66	Patient (n=81 with refractory seizures)	Time trade off	
325	Suboptimal seizure control (2-9 seizures/month) on lamotrigine	0.79	Patient (n=81 with refractory seizures)	Time trade off	
325	Nearly complete seizure control (<=1 seizure/mo) on lamotrigine	0.91	Patient (n=81 with refractory seizures)	Time trade off	
325	Complete response (no seizures in past year) on lamotrigene	0.96	Patient (n=81 with refractory seizures)	Time trade off	
7. Diseases of the Circulatory System					
Angina					
270	Cornary Artery disease	0.786	Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
271	Angina with no chest pain symptoms	0.87	Patient (211 patients with chronic stable angina)	Standard gamble	

271	Mild chest pain symptoms	0.81		Patient (211 patients with chronic stable angina)	Standard gamble	
302	Mild activity restriction	0.95		Not stated	Unknown	
302	Moderate to severe restriction	0.8		Not stated	Unknown	
271	Severe chest pain symptoms	0.67		Patient (211 patients with chronic stable angina)	Standard gamble	
311	QOL 6mo post hospitalization for acute coronary syndrome that had been treated with placebo	0.83		Patient (n=1978 US patients enrolled in PURSUIT study) N Engl J Med 1998	Time trade off	
311	QOL 6mo post hospitalization for acute coronary syndrome that had been treated with Eptifibatide	0.84		Patient (n=1978 US patients enrolled in PURSUIT study) N Engl J Med 1998	Time trade off	
Anticoagulation						
239	Life after CNS bleeding complication	0.29		Patients (36 patients, 16 with DVT, 20 without)	Standard Gamble	
251	Warfarin	0.988		Patient (48 patients attending the local anticoagulation clinic Italy)	Time trade off	
251	Low molecular weight heparin	0.992		Patient (48 patients attending the local anticoagulation clinic Italy)	Time trade off	
261	Warfarin treatment	0.987	.92-1	Patients (74 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
261	Aspirin treatment	0.998	.96-1	Patients (74 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
275	Major Bleeding	0.986		Author	Length of Stay	
275	Minor Bleeding	0.997		Author	Length of Stay	
283	Temporary disability following major GI hemorrhage	0.5	.3-.7	Not stated	Unknown	
285	Permanent bleeding sequelae	0.6		Community		Rosser Index (given to 206 patients, 100 Q wave MI, 60 non Q wave and other non-confirmed)

285	Well while receiving aspirin	1	Community		Rosser Index (given to 206 patients, 100 Q wave MI, 60 non Q wave and other non-confirmed)
308	Permanent bleeding sequelae from anticoagulants	0.6	Author	Author/Clinician Judgement	
308	Bleeding event with resolution (duration 1 month)	0.87	Author	Author/Clinician Judgement	
308	Well while receiving anticoagulants	0.99	Author	Author/Clinician Judgement	
378	Hemorrhage	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
444	Warfarin treatment in pt at low risk for stroke	0.949	Patient (with atrial fibrillation and at least 50 years of age and could read English, 83 volunteers and used results from 69)	TTO	U-titer
444	Aspirin treatment in pt at low risk for stroke	0.995	Patient (with atrial fibrillation and at least 50 years of age and could read English, 83 volunteers and used results from 69)	TTO	U-titer
509	Permanently disabling event associated with anticoagulation therapy	0.5	Not stated	Unknown	
509	Temporarily disabling event associated with anticoagulation therapy	0.75	Not stated	Unknown	
Cardiac Arrhythmia					

243	Patients with frequent vasovagal syncope (median 0.5 spells per month) baseline pre-pacemaker	0.63	.42-.84	Community	Time trade off □ Rating scale	EQ5D (EuroQoL) given to patients (25 patients treated with pacemakers for vasovagal syncope)
243	Patients with frequent vasovagal syncope (median 0.5 spells per month) post-pacemaker	0.76	.61-.91	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients (25 patients treated with pacemakers for vasovagal syncope)
261	Amidaron treatment	0.987	.92-1	Author	Author/clinician judgement	
310	Amiodarone for patients with ventricular tachycardia	0.74		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone success without adverse event from treatment for VT	0.81		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale

267	Amiodarone use with mild side effects	0.73		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
310	Amiodarone failure without adverse event from treatment for VT	0.65		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Failure with no further treatment from treatment for VT	0.65		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
261	Chronic pulmonary toxicity	0.6	.4-1	Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)

310	Mild/moderate pulmonary toxicity from treatment for VT	0.44		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone success with permanent neurological impairment from treatment for VT	0.47		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone failure with permanent neurological impairment from treatment for VT	0.32		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale

310	Mild/moderate neurological impairment from treatment for VT	0.55		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone success with permanent hepatic toxicity from treatment for VT	0.61		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone failure with permanent hepatic toxicity from treatment for VT	0.46		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale

310	Mild hepatic toxicity from treatment for VT	0.79		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone success with permanent hyperthyroidism from treatment for VT	0.66		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Amiodarone failure with permanent hyperthyroidism from treatment for VT	0.53		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale

310	Hypothyroidism from treatment for VT	0.78		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Ablation success with permanent thromboembolic event from treatment for VT	0.54		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Impotence from treatment for VT	0.65		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale

310	Skin discoloration/photosensitivity from treatment for VT	0.68		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Mild/moderte ocular impairment from treatment for VT	0.76		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Symptomatic bradycardia from treatment for VT	0.76		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
261	Quindine treatment	0.996	.96-1	Author	Author/clinician judgement	
261	Well in sinus rhythm	1	.98-1	Author	Author/clinician judgement	

310	Ablation success without adverse event from treatment for VT	0.89		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
267	Implantable cardioverter defibrillator with severe rate of device-related side effects	0.64		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
267	Implantable cardioverter defibrillator with moderate rate of device-related side effects	0.75		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
267	Implantable cardioverter defibrillator with low rate of device-related side effects	0.76		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
269	Complications of radiofrequency ablation	0.997		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	
269	Unscheduled physician visit	0.9993		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	

269	Patients with AV nodal block	0.776		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	
269	Patients with Supraventricular tachycardia (SVT) treated only with episodic abortive drugs	0.828		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	
269	Patients with SVT on long term drug therapy	0.833		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	
269	Patients with SVT cured following radiofrequency ablation	0.983		Patient (161 patients 70% women, physically active , and symptomatic for a median of 3 years)	Time trade off	
285	Well in atrial fibrillation	0.95		Community		Rosser Index (given to 206 patients, 100 Q wave MI, 60 non Q wave and other non-confirmed)
285	Well in normal sinus rhythm	1		Community		Rosser Index (given to 206 patients, 100 Q wave MI, 60 non Q wave and other non-confirmed)

310	Ablation failure with permanent thromboembolic event from treatment for VT	0.42		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Ablation failure without adverse event from treatment for VT	0.75		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
310	Catheter ablation in patients with ventricular tachycardia	0.77		Patient/Clinician	Rating scale	SF-36(107 patients with documented sustained monomorphic VT with 2 or more episodes during the 2 months before enrollment) transformed, then Clinicians panel ranked on a rating scale
358	Electrophysiologic cardiac testing	0.962		Not stated	Unknown	
	Cardiac/Cerebral Investigations & Procedures					

277	Medical treatment of Coronary Artery Disease	0.61	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients (176 surgically managed and 48 medically managed octogenarians treated for CAD at Columbia Presbyterian Medical Center (CPMC) between 1992 and 1996)
277	Medical treatment of Coronary Artery Disease, refused surgery	0.74	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients (176 surgically managed and 48 medically managed octogenarians treated for CAD at Columbia Presbyterian Medical Center (CPMC) between 1992 and 1996)
277	Surgery for Coronary Artery Disease	0.84	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients (176 surgically managed and 48 medically managed octogenarians treated for CAD at Columbia Presbyterian Medical Center (CPMC) between 1992 and 1996)

378	Coronary artery bypass grafting surgery	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Coronary artery angioplasty	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Carotid thromboendarterectomy	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)

378	Surgery of the aorta	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Aortoiliac surgery	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Infrainguinal surgery, contralateral leg	0.58	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)

378	Infrainguinal surgery, ipsilateral leg	0.58		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Other vascular surgery	0.58		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	No event	0.68		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
534	life after primary balloon angioplasty in myocardial infarction	0.83		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients with acute MI receiving balloon angioplasty n=448)

534	life after stent primary angioplasty in myocardial infarction	0.85	Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to patients with acute MI receiving coronary stenting n=452)
Congestive Heart Failure					
244	Heart failure	0.5	Not stated	Unknown	
270	Congested Heart Failure	0.71	Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
270	Cure	1	Not stated	Unknown	
Deep Vein Thrombosis/Pulmonary Embolism					
239	Severe postphlebitic Syndrome (assuming a baseline of 1)	0.977		Patients (36 patients, 16 with DVT, 20 without)	Standard Gamble
251	severe post thrombophlebitis syndrome	0.96	Community		Standard Gamble
275	Severe Postphlebitic Syndrome	0.93	Community		Standard Gamble
275	Mild Postphlebitic Syndrome	1	Community		Standard Gamble
275	Pulmonary Embolism	0.978	Author		Length of Stay
275	Recurrent DVT	0.984	Author		Length of Stay
275	Thrombocytopenia	0.997	Author		Length of Stay
285	Permanent thromboembolic sequelae	0.5	Community		Rosser Index (given to 206 patients, 100 Q wave MI, 60 non Q wave and other non-confirmed)
301	Pulmonary emboli	0.5	Author		Unknown
308	Permanent thromboembolic sequelae	0.5	Author		Author/Clinician Judgement
308	Thromboembolic event with resolution (duration 1 month)	0.7	Author		Author/Clinician Judgement
432	Severe post-Thrombophebitis syndrome	0.995		Patients (36 patients, 16 with DVT, 20 without)	Standard Gamble
516	Short stay in hospital (for major bleeding or recurrent DVT)	0.5	Author		Unknown
Hypertension					

365	After stroke	0.8		Patient (n not given)	Torrance transformation of rating scale	
365	after coronary heart disease	0.9		Patient (n not given)	Torrance transformation of rating scale	
365	Undergoing treatment for hypertension	0.99		Patient (n not given)	Torrance transformation of rating scale	
365	Hypertensive person	1		Patient (n not given)	Torrance transformation of rating scale	
Myocardial Infarction						
267	Post-myocardial infarction	0.88		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
267	Implantable cardioverter defibrillator post-myocardial infarction	0.88		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
267	Amiodarone use post-myocardial infarction	0.88		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
267	Acute drug toxicity	0.997		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	TTO	
274	Statin Treatment	0.987		Author	Author/clinician judgement	
283	Alive after MI	0.88	.8-.95	Not stated	Unknown	
292	Death	0.023		Not stated	Unknown	
292	Myocardial Infarction (Q Wave)	0.84		Not stated	Unknown	
292	Non Q - Wave Myocardial Infarction	0.912		Not stated	Unknown	

303	<=65 years old patients with an acute MI and clinical evidence of heart failure	0.786		Not stated	Unknown	
303	>65 years old patients with an acute MI and clinical evidence of heart failure	0.932		Not stated	Unknown	
309	Survivor of cardiac arrest	0.72		Patient	Unknown	
323	General population aged 60-79	0.8		Not stated	Unknown	
323	Myocardial infarction	0.7		Author	Author/Clinician Judgement	
344	Incremental utility for MI treated with thrombolysis	0.132		Not stated	Unknown	
378	Myocardial infarction	0.58		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
380	Myocardial infarction	0.87		Not stated	Unknown	
383	Beta-blocker use after myocardial infarction	1		Author	Unknown	
390	Severely impaired survivor of cardiac arrest	0	0-.5	Community	Standard gamble; Rating scale	Health Utilities Index (given patients at a mean of 9.9 months after Cardiac arrest)n not given
390	Moderately impaired survivor of cardiac arrest	0.07	0-.38	Community	Standard gamble; Rating scale	Health Utilities Index (given patients at a mean of 9.9 months after Cardiac arrest)n not given
390	Unimpaired survivor of cardiac arrest	0.78	.56-1	Community	Standard gamble; Rating scale	Health Utilities Index (given patients at a mean of 9.9 months after Cardiac arrest)n not given
523	Reinfrarcton and congestive heart failure	0.82		Patient (9385 patients presenting to General Practicioners office)	Unknown	

523	Asymptomatic left ventricular dysfunction state	1		Patient (67 patients who had a recent MI, an ejection fraction less than 0.4, and no congestive heart failure)	Time trade off	
531	post-MI patients	0.85		Author	Author/clinician judgement	
Peripheral Vascular Disease						
238	After failure of treatment of iliac artery occlusive disease	0.7		Patients	Unknown	
238	Successfully treated iliac artery occlusive disease	0.82		Patients	Unknown	
304	Expectant management: remain the same with limb threatening ischemia	0.4		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Not ambulate after reamputation	0.45		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Not ambulate after failed revascularization/amputation for limb threatening ischemia	0.45		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Not ambulate after primary amputation	0.5		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Ambulate after reamputation	0.55		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Ambulate after failed revascularization/amputation for limb threatening ischemia	0.57		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Ambulate after primary amputation	0.6		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	

304	Success after multiple revascularization for limb threatening ischemia	0.9		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
304	Success after revascularization for limb threatening ischemia	0.95		Patient (64 patients with symptoms of infrainguinal vascular occlusive disease)	Time trade off	
376	Abdominal aortic aneurysm (AAA) regardless of rx	0.86		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
378	Occlusion	0.58		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
380	open surgical repair of AAA	0.871		Not stated	Unknown	
380	endovascular surgical repair of AAA	0.97		Not stated	Unknown	
381	ruptured AAA operative repair	0.858		Not stated	Unknown	
437	After failure of treatment of intermittent claudication caused by an iliac arterial stenosis	0.7		Community	Standard gamble; Rating scale	Health Utilities Index given to community n not stated
437	Successful treatment of intermittent claudication caused by an iliac arterial stenosis	0.82		Community	Standard gamble; Rating scale	Health Utilities Index given to community n not stated
Stroke						
236	Living with neurologic deficit in patient with cerebral aneurysm	0.76		Author	Author/clinician judgement	
236	Living with Guglielmi Detachable Coiled embolized aneurysm	1		Author	Author/clinician judgement	
236	Living with unruptured, untreated aneurysm	1		Author	Author/clinician judgement	
250	Permanent disability due to hemorrhagic stroke	0.5		Not stated	Unknown	

251	Stroke	0.5		Community	Standard Gamble	
261	Patients with a stroke with intracranial bleeding with moderate to severe residua	0.39	0-1	Patients (74 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
261	Patients with a stroke with intracranial bleeding with mild residua	0.76	.14-1	Patients (74 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
270	Stroke	0.64	.35-.93	Community	Standard gamble □ Rating scale	Health Utilities Index (given to 74 patients with ischemic stroke and 37 family caregivers)
270	Valve Replacement (cardiac)	0.988	.92-1	Patients (74 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
274	Patients > 75 yo ≤ 1 year after stroke	0.76		Patient (Patients > 75 yo who experienced various levels of disability from in-hospital stroke after myocardial infarction and in patients who did not have a stroke in a substudy of Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-I) n not given)	Time trade off	
274	Patients >75 yo ≤ 1 year after recurrent myocardial infarction	0.8		Patient (Patients > 75 yo who experienced various levels of disability from in-hospital stroke after myocardial infarction and in patients who did not have a stroke in a substudy of Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-I) n not given)	Time trade off	

274	Patients >75 yo >1 year after stroke	0.83		Patient (Patients > 75 yo who experienced various levels of disability from in-hospital stroke after myocardial infarction and in patients who did not have a stroke in a substudy of Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-I) n not given)	Time trade off	
274	Patients > 75 yo >1 year after recurrent myocardial infarction	0.87		Patient (Patients > 75 yo who experienced various levels of disability from in-hospital stroke after myocardial infarction and in patients who did not have a stroke in a substudy of Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-I) n not given)	Time trade off	
283	Long-term disability after stroke	0.5	.3-.7	Not stated	Unknown	
283	Alive after nondisability stroke	0.8	.7-.9	Not stated	Unknown	
283	Alive, free of stroke	1		Not stated	Unknown	
360	Esophageal perforation (for one month)	0.9		Not stated	Unknown	
360	Long term atrial fibrillation	1		Not stated	Unknown	
364	Major Stroke	0.25		Not Stated	Unknown	
364	Minor Stroke	0.75		Not Stated	Unknown	
364	Transient Ischemic Attack (TIA)	0.9		Not Stated	Unknown	
369	Survival with more severe neurological deficit after surgery for intracranial aneurysm	0.5		Not stated	Unknown	
369	Survival with less severe neurological deficit after surgery for intracranial aneurysm	0.75		Not stated	Unknown	
370	Stroke-free with unilateral occluded internal carotid artery	0.9		Patients (70 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
377	Major stroke	0.2		Not stated	Unknown	
377	Minor stroke	0.8		Not stated	Unknown	

378	Stroke	0.45		Community	Time trade off □ Rating scale	EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
379	Major stroke	0.4		Patients (117 stroke patients)	Rank and Scale	
379	Minor stroke	0.75		Patients (117 stroke patients)	Rank and Scale	
380	Stroke	0.4		Not stated	Unknown	
402	No health side effects from aneurism/treatment	1		Author	Author/Clinician judgment	
402	Untreated aneurism with no symptoms		1- 5 times the rate of rupture	Community	Author/clinician judgement; Rating scale; Standard gamble	Health Utilities Index used by Author
402	Perm. mod/severe disability	0.25		Author	Author/clinician judgement	
402	Untreated aneurism with mild symptoms	0.84		Community	Standard gamble; Author/clinician judgement; Rating scale	Health Utilities Index used by Author
403	Severe disability (Rankin 5)	-0.02		Patient (117 at risk for stroke)	Rank and Scale	
403	Moderate/severe disability (Rankin 4)	0.3		Patient (117 at risk for stroke)	Rank and Scale	
403	Moderate disability (Rankin 3)	0.34		Patient (117 at risk for stroke)	Rank and Scale	
403	Slight disability (Rankin 2)	0.46		Patient (117 at risk for stroke)	Rank and Scale	
403	No disability despite symptoms (Rankin 1)	0.8		Patient (117 at risk for stroke)	Rank and Scale	
403	No symptoms (Rankin score 0)	0.9		Patient (117 at risk for stroke)	Rank and Scale	
418	Not disabled - including mild residual Post stroke	0.85		Patients (70 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
423	Ischemic stroke with Rankin score 5 (severe disability)	-0.02		Author	Author/clinician judgement	
423	Ischemic stroke with Rankin score 4 (moderate to severe disability)	0.3		Author	Author/clinician judgement	

423	Ischemic stroke with Rankin score 3 (moderate disability)	0.34		Author	Author/clinician judgement	
423	Ischemic stroke with Rankin score 2 (minimal disability)	0.46		Author	Author/clinician judgement	
423	Ischemic stroke with Rankin score 1 (no significant disability)	0.8		Author	Author/clinician judgement	
423	Ischemic stroke with Rankin score 0 (no symptoms)	0.9		Author	Author/clinician judgement	
432	Disability after stroke	0.29		Patients (70 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
444	2nd stroke	0.15		Patient (with atrial fibrillation and at least 50 years of age and could read English, 83 volunteers and used results from 69)	TTO	U-titer
444	Mod-severe stroke	0.51		Patient (with atrial fibrillation and at least 50 years of age and could read English, 83 volunteers and used results from 69)	TTO	U-titer
444	Mild stroke	0.85		Patient (with atrial fibrillation and at least 50 years of age and could read English, 83 volunteers and used results from 69)	TTO	U-titer
446	Major stroke	0.4		Author	Author/clinician judgement	
446	Minor stroke for three months	0.75		Author	Author/clinician judgement	
480	Stroke or neurological deficit	0.75		Not stated	Unknown	
500	Surviving with a stroke	0.4		Author	Unknown	
500	Amputation of lower extremity	0.8		Author	Unknown	
505	Postoperative recovery for asymptomatic unruptured intracranial aneurysm	0.6		Author	Author/clinician judgement	
505	Disabled after subarachnoid hemorrhage or surgery for asymptomatic intracranial aneurysm	0.7		Author	Author/clinician judgement	
505	well without screening for asymptomatic intracranial aneurysm	1		Author	Author/clinician judgement	

516	Disability after stroke	0.6		Patients (70 patients with atrial fibrillation)	Standard Gamble/Time Trade Off	
	Valvular heart Disease/Thromboembolism					
253	Survived endocarditis with valve replacement	0.9		Not stated	Time trade off	
253	Survived endocarditis without valve replacement	0.95		Not stated	Time trade off	
253	Valve replacment surgery	0.962		Not stated	Time trade off	
253	Endocarditis	0.973		Not stated	Time trade off	
253	Inappropriate endocarditis treatment	0.986		Not stated	Time trade off	
253	Transesophageal echocardiogram	0.99994		Not stated	Time trade off	
270	Valve Replacement	0.988		Not stated	Unknown	
312	Vancomycin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with vancomycin toxicity	0.75		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with survived penicillin reaction	0.82		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with no vancomycin toxicity	0.85		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis with no penicillin allergy skin test and vancomycin toxicity	0.87		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment failure for staphylococcal endocarditis with no penicillin allergy skin test and no vancomycin toxicity	0.875		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment failure for staphylococcal endocarditis following penicillin allergy skin test, with no penicillin reaction	0.885		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with vancomycin toxicity	0.9		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with survived penicillin reaction	0.92		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis with no penicillin allergy skin test and vancomycin toxicity	0.92		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	

312	Vancomycin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with no vancomycin toxicity	0.95		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Vancomycin treatment curing staphylococcal endocarditis with no penicillin allergy skin test and no vancomycin toxicity	0.97		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
312	Cloxacillin treatment curing staphylococcal endocarditis following penicillin allergy skin test, with no penicillin reaction	0.985		Clinician (head nurse caring for patients with endocarditis)	Standard gamble	
8. Diseases of the Respiratory System						
Acute Respiratory Failure						
254	Pts with acute respiratory failure who require ventilation support in an intensive care unit	0.88	SD.22	Patient (225 patients at 6 months post treatment who had required ventilatory support for acute respiratory failure)	Time trade off	
359	Seriously ill patients with acute respiratory failure	0.88		Patient (1005 patients >18 yo, inpatients from June 1989 to Jan 1994 at five geographically diverse academic medical centers USA with acute respiratory failure and received ventilator support.	Time trade off	
354	Diagnosis: Acute respiratory failure (no Chronic Respiratory Disease)	0.61		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Acute respiratory failure (with CRD)	0.52		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
Chronic Respiratory Disease						

307	Acute exacerbation of chronic bronchitis treated with usual care (defined as antibiotic or combination of antibiotics other than a quinolone)	0.76		Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen with chronic bronchitis, with a recent history of frequent exacerbations n=240 (120 in each group)
420	Mean utility during first acute exacerbation of chronic bronchitis with usual care n=107	0.68	SD.19	Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen in 46 family physicians and 2 respirologists in Ontario n= 240 aged >18 with chronic bronchitis
307	Acute exacerbation of chronic bronchitis treated with ciprofloxacin	0.791		Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen with chronic bronchitis, with a recent history of frequent exacerbations n=240 (120 in each group)
420	Mean utility during first acute exacerbation of chronic bronchitis with Ciprofloxacin n=115	0.72	SD.2	Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen in 46 family physicians and 2 respirologists in Ontario n= 240 aged >18 with chronic bronchitis
420	Mean utility during remaining exacerbations of chronic bronchitis with usual care n=107	0.69	SD.22	Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen in 46 family physicians and 2 respirologists in Ontario n= 240 aged >18 with chronic bronchitis

420	Mean utility during remaining exacerbations of chronic bronchitis with Ciprofloxacin n=115	0.74	SD.18	Community	Standard gamble; Rating scale	Health Utilities Index given to patients seen in 46 family physicians and 2 respirologists in Ontario n= 240 aged >18 with chronic bronchitis
327	Chronic hypoxemia before treatment with liquid oxygen	0.5076		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 47 patients with chronic hypoxaemia presenting for treatment in Sweden
327	Chronic hypoxemia after oxygen concentrator treatment	0.5329		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 47 patients with chronic hypoxaemia presenting for treatment in Sweden
327	Chronic hypoxemia after treatment with liquid oxygen	0.534		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 47 patients with chronic hypoxaemia presenting for treatment in Sweden
327	Chronic hypoxemia before oxygen concentrator treatment	0.5353		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to 47 patients with chronic hypoxaemia presenting for treatment in Sweden
447	Patients with chronic lung disease receiving standard care n=101; Prior to entering the study	0.34		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed
447	Patients with chronic lung disease receiving 6 week rehabilitation programme n=99; Prior to entering the study	0.33		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed

447	Patients with chronic lung disease receiving standard care n=101; 6 weeks after entering the study	0.37		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed
447	Patients with chronic lung disease receiving 6 week rehabilitation programme n=99; 6 weeks after entering the study	0.43		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed
354	At 6 months with chronic respiratory disease; Global	0.63		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	At 6 months with chronic respiratory disease; Age < 40 years	0.93		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	At 6 months with chronic respiratory disease; Age 40 < 65 years	0.58		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	At 6 months with chronic respiratory disease; Age >= 65 years	0.63		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
447	Patients with chronic lung disease receiving standard care n=101; 12 months after entering the study	0.4		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed
447	Patients with chronic lung disease receiving 6 week rehabilitation programme n=99; 12 months after entering the study	0.4		Community	Transformed SF-6D from SF-36	SF-36/12 given to 200 patients disabled with lung disease, transformed
Cystic Fibrosis						

526	Individual with cystic fibrosis	0.7		Patient or Relatives/Proxies (All families with CF children cared for in the Cystic Fibrosis Clinic of the University of Rochester Medical Center were invited to participate numbers not given	Time trade off	
526	Mother of child with cystic fibrosis	0.9		Patient or Relatives/Proxies (All families with CF children cared for in the Cystic Fibrosis Clinic of the University of Rochester Medical Center were invited to participate numbers not given	Time trade off	
526	Father of child with cystic fibrosis	0.95		Patient or Relatives/Proxies (All families with CF children cared for in the Cystic Fibrosis Clinic of the University of Rochester Medical Center were invited to participate numbers not given	Time trade off	
	Obstructive Airways Disease/Sleep Apnea					
265	No obstructive sleep apnea, on CPAP	0.63		Author	Author/clinician judgement	
265	Obstructive sleep apnea, not on CPAP	0.63		Author	Author/clinician judgement	
265	No obstructive sleep apnea, not on CPAP	0.75		Author	Author/clinician judgement	
265	Obstructive sleep apnea, on CPAP (Continuous Positive Airway Pressure)	0.87		Author	Standard gamble	
	Lung Transplant/End Stage Pulmonary Disease					

306	End-stage pulmonary disease with Life Expectancy 12-18 mos.	0.52		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303
306	End-stage pulmonary disease 1-3 mos. before death	0.3		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303
345	End-stage pulmonary disease in 3 mos. prior to death	0.31		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
306	End-stage pulmonary disease on lung transplant waiting list 0-6 mos.	0.55		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303
345	End-stage pulmonary disease on lung transplant waiting list 0-6 mos.	0.55		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)

345	End-stage pulmonary disease on lung transplant waiting list 6-9 mos.	0.5		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	End-stage pulmonary disease on lung transplant waiting list 9-12 mos.	0.45		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	End-stage pulmonary disease on lung transplant waiting list 12-15 mos.	0.4		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	End-stage pulmonary disease on lung transplant waiting list >15 mos.	0.4		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
306	End-stage pulmonary disease 1-3 mos. before death on lung transplant waiting list	0.31		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303

306	In-hospital following lung transplantation	0.69		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303
345	After lung transplantation, <1 mo.	0.69		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	After lung transplantation, 1-3 mos.	0.83		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	After lung transplantation, 4-6 mos.	0.85		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	After lung transplantation, 7-12 mos.	0.84		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)

345	After lung transplantation, 13-19 mos.	0.86		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
345	After lung transplantation, 20-25 mos.	0.91		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
306	After lung transplantation, 1st 2 yrs.	0.85		Community	Rating scale; Time trade off	EQ5D (EuroQoL) Given to patients who entered the Dutch lung transplantation program from Nov 1990 to April 1995 n=303
345	After lung transplantation, >25 mos.	0.9		Community	Rating scale; Time trade off	EQ5D (EuroQoL) given patients (425 patients referred for lung transplantations with 57 consecutive transplantations)
Respiratory Infections						
284	Average health between 65 and 85 years old	0.71		Community	HAlex, US National Health Interview Survey Erickson P et al Year of health life National Center for Health Statistics. Statistical Notes No 7 1-14 April 1995	Years of Healthy Life

284	Bed-disability days with pneumonia or influenza	0.4	Not stated	Unknown	US Congress OTA Cost-effectiveness Analysis of Influenza Vaccination. Washington, DC OTA 1981
284	Non-bed-disability days with pneumonia or influenza	0.6	Not stated	Unknown	US Congress OTA Cost-effectiveness Analysis of Influenza Vaccination. Washington, DC OTA 1981
315	Hospitalized with pneumonia	0.85	Author	Author/clinician judgement	
315	Outpatient pneumonia	0.9	Author	Author/clinician judgement	
315	Convalescence from pneumonia	0.9	Author	Author/clinician judgement	
415	Day with Influenza Symptoms	0.5579	Community	Rating scale	QWB Scale applied by the author
419	Influenza - patients -Worst Day (assume starting at 1)	0.658	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients aged >18, n=21, then GP panel n=8
419	Influenza - physicians - Illness (assume starting at 1)	0.737	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients aged >18, n=21, then GP panel n=8
419	Influenza - patients -Illness (assume starting at 1)	0.934	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients aged >18, n=21, then GP panel n=8
315	Severe side effects from pneumococcal vaccination, not requiring hospitalization	0.9	Author	Author/clinician judgement	
315	Hospitalized with anaphylaxis	0.85	Author	Author/clinician judgement	
517	Hospitalization with respiratory syncytial virus in the elderly	0.35	Author	Author/clinician judgement	
517	Nursing home with respiratory syncytial virus in the elderly	0.46	Author	Author/clinician judgement	
517	Outpatient illness with respiratory syncytial virus in the elderly	0.76	Author	Author/clinician judgement	

288	Adult with severe shortness of breath (Value for one day)	0.68		Community	Rating scale; Unknown	QWB Scale (not stated to whom it was given)
290	Patients with Wegener's Granulomatosis undergoing immunosuppressive therapy who contract Pnumocystis carinii pneumonia (PCP) (For 1 year)	0.3		Clinician	Author/clinician judgement	
290	Patients with Wegener's Granulomatosis undergoing immunosuppressive therapy who experience an adverse drug reaction (For 1 year)	0.9		Clinician	Author/clinician judgement	
9. Diseases of the Digestive System						
Gastrointestinal Bleeding						
264	Variceal hemorrhage	0.55	.39-.71	Clinician (Expert panel n not given)	Standard gamble and Time trade off	
471	Variceal hemorrhage, 1 year	0.5		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Variceal hemorrhage, following years after 1 year	0.6		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
491	Variceal hemorrhage	0.55		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and Time trade off	
540	Variceal haemorrhage, first year	0.28		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off	
540	Variceal haemorrhage, subsequent years	0.28		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off	
Hepatitis						
264	Hepatic encephalopathy	0.53	.36-.7	Clinician (Expert panel n not given)	Standard gamble and Time trade off	
264	Moderate chronic hepatitis C	0.92	.82-1	Clinician (Expert panel n not given)	Standard gamble and Time trade off	
264	Viral positive Hepatitis C	0.95	.25-1	Clinician (Expert panel n not given)	Standard gamble and Time trade off	
264	Mild chronic hepatitis C	0.98	.95-1	Clinician (Expert panel n not given)	Standard gamble and Time trade off	

264	Combination therapy	0.981		Clinician (Expert panel n not given)	Standard gamble and Time trade off	
339	Acute hepatitis	0.918		Author	Author/clinician judgement	
339	Well but susceptible	1		Author	Author/clinician judgement	
339	Well with natural immunity	1		Author	Author/clinician judgement	
339	Well with vaccine immunity	1		Author	Author/clinician judgement	
411	Chronic hepatitis	0.9	.82-1	Not stated	Unknown	
448	Symptomatic acute hepatitis	0.7		Not stated	Unknown	
448	Chronic hepatitis	0.9		Not stated	Unknown	
448	Asymptomatic chronic hepatitis C carrier	1		Not stated	Unknown	
449	Myelopathy	0.423		Author	Author/clinician judgement	
450	Chronic hepatitis	0.94		Clinician (Expert panel n not given)	Standard gamble and Time trade off	
471	Interferon alpha-2b with ribavirin treatment for chronic hepatitis C	0.7		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Interferon treatment for chronic hepatitis C	0.8		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Chronic hepatitis	0.9		Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
472	Chronic hepatitis C	0.82		Community	Standard gamble □ Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
472	Interferon/ribavirin treatment side effects (assume a baseline of 1)	0.91		Community	Standard gamble □ Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
487	Severe HCV disease (decompensated cirrhosis and hepatocellular carcinoma)	0.26		Author	Unknown	
487	Chronic Hepatitis	0.78		Author	Unknown	

491	Moderate chronic hepatitis	0.92		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and Time trade off	
491	Positive for HCV	0.95		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and Time trade off	
491	Mid chronic hepatitis	0.98		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and Time trade off	
495	Chronic hepatitis C virus infection	0.95		Clinician (expert panel of hepatologists and nurse clinician n not given)	Unknown	
495	Treatment with interferon alfa	0.95		Clinician (expert panel of hepatologists and nurse clinician n not given)	Unknown	
495	Resolved hepatitis C infection	1		Clinician (expert panel of hepatologists and nurse clinician n not given)	Unknown	
497	Chronic Hepatitis: Treatment with luterferond	0.467		Community		Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)
497	Chronic Hepatitis: Treatment with lamivudine	0.611		Community		Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)
497	Chronic Hepatitis: No Treatment	0.692		Community		Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)

					Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)
497	Seroconverted	0.783		Community	
501	Acute symptomatic hepatitis (for 3-months)	0.7		Not stated	Unknown
501	chronic symptomatic hepatitis	0.9		Not stated	Unknown
501	Without complications	1		Not stated	Unknown
533	Combination treatment (due to side effects)	0.9		Author	Unknown
533	Chronic hepatitis C	0.96		Author	Unknown
533	Learning a positive test result for hepatitis	0.98		Author	Unknown
540	Moderate hepatitis C	0.78		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Mild chronic hepatitis C	0.82		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Viral negative	1		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
	Cirrhosis + Sequelae				
244	Cirrhosis	0.8		Not stated	Unknown
264	Ascites, diuretic refractory	0.52	.38-.66	Clinician (Expert panel n not given)	Standard gamble and Time trade off
264	Ascites, diuretic sensitive	0.75	.54-.96	Clinician (Expert panel n not given)	Standard gamble and Time trade off
264	Compensated cirrhosis	0.82	.64-1	Clinician (Expert panel n not given)	Standard gamble and Time trade off
264	Liver transplantation	0.86	.76-.96	Clinician (Expert panel n not given)	Standard gamble and Time trade off
411	Decompensated cirrhosis	0.7	.5-1	Not stated	Unknown
411	1st yr. post-orthotopic liver transplantation	0.8	.7-1	Not stated	Unknown
411	Compensated cirrhosis	0.85	.8-1	Not stated	Unknown
411	Subsequent yr. post-orthotopic liver transplantation	0.9	.8-1	Not stated	Unknown
448	Decompensated cirrhosis	0.5		Not stated	Unknown
448	Liver transplant, 1st quarter	0.5		Not stated	Unknown
448	Liver transplant, 2nd-4th quarter	0.75		Not stated	Unknown
448	Liver transplant, 2nd and subsequent yrs.	0.85		Not stated	Unknown
450	Compensated Cirrhosis	0.92		Clinician (Expert panel n not given)	Standard gamble and Time trade off

471	Ascites, refractory	0.2	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Encephalopathy	0.2	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Partial hepatectomy, 1 year (cirrhosis)	0.4	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Ascites, diuretic sensitive	0.5	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Partial hepatectomy, following years after 1 year (cirrhosis)	0.5	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Orthotopic liver transplantation, 1 year	0.7	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Compensated cirrhosis	0.75	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
471	Orthotopic liver transplantation, following years after 1 year	0.8	Clinician (Swiss physicians, 2 gastroenterologists and three hepatologists)	Time trade off	
472	Liver transplantation, first year	0.5	Community	Standard gamble; Rating scale	Health Utilities Index (given to patients with liver disease n not given)

472	Decompensated cirrhosis	0.65	Community	Standard gamble; Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
472	Liver transplantation, succesive years after first	0.7	Community	Standard gamble; Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
472	Compensated cirrhosis	0.78	Community	Standard gamble; Rating scale	Health Utilities Index (given to pateints with liver disease n not given)
487	Cirrhosis	0.7	Author	Unknown	
491	Ascites- Diuretic refractory	0.52	Clinician (expert panal of senior hepatologists n not given)	Standard gamble and Time trade off	
491	Hepatic encephalopathy	0.53	Clinician (expert panal of senior hepatologists n not given)	Standard gamble and Time trade off	
491	Ascites- diuretic sensitive	0.75	Clinician (expert panal of senior hepatologists n not given)	Standard gamble and Time trade off	
491	Compensated cirrhosis	0.82	Clinician (expert panal of senior hepatologists n not given)	Standard gamble and Time trade off	
495	Advanced liver failure	0.25	Clinician (expert panal of hepatologists and nurse clinician n not given)	Unknown	
495	Cirrhosis	0.75	Clinician (expert panal of hepatologists and nurse clinician n not given)	Unknown	
497	Decompensated Cirrhosis	0.15	Community		Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)

					Assessment of Quality of Life Questionnaire (given to 4 members of an expert panel)
497	Compensated Cirrhosis	0.561		Community	
501	Decompensated cirrhosis	0.5		Not stated	Unknown
533	Decompensated cirrhosis	0.56		Author	Unknown
533	Compensated cirrhosis	0.8		Author	Unknown
533	Liver transplantation (1st year)	0.8		Author	Unknown
533	Liver transplantation (after 1st year)	0.95		Author	Unknown
540	Hepatic encephalopathy, first year	0.3		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Hepatic encephalopathy, subsequent years	0.3		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Diuretic-sensitive ascites	0.35		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Diuretic-refractory ascites	0.35		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Liver transplant, first year	0.5		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Compensated cirrhosis	0.7		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
540	Liver transplant, subsequent years	0.7		Clinician (expert panel of senior hepatologists n not given)	Standard gamble and time trade off
	Nausea, Vomiting and Bowel				
328	Crohn's disease patient with acute pancreatitis and perianal fistula treated with 6MP/met	0.61		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble
328	Crohn's disease patient with perianal abscess treated with infliximab	0.62		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble

328	Crohn's disease patient with paresthesias and perianal fistula treated with 6MP/met	0.66		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with acute pancreatitis and perianal fistula treated with 6MP/met (healthy individual)	0.68		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with paresthesias and perianal fistula treated with 6MP/met (healthy individual)	0.68		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with perianal fistula treated with 6MP/met	0.69		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with acute pancreatitis and improved perianal fistula treated with 6MP/met	0.7		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with perianal abscess treated with infliximab (healthy individual)	0.72		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with perianal fistula treated with infliximab	0.73		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with paresthesias and improved perianal fistula treated with 6MP/met	0.75		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with perianal fistula treated with 6MP/met (healthy individual)	0.75		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with perianal fistula treated with infliximab (healthy individual)	0.77		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with acute pancreatitis and improved perianal fistula treated with 6MP/met (healthy individual)	0.79		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with improved perianal fistula treated with 6MP/met	0.81		Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	

328	Crohn's disease with paresthesias and improved perianal fistula treated with 6MP/met (healthy individual)	0.84	Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease patient with improved perianal fistula treated with infliximab	0.85	Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with improved perianal fistula treated with 6MP/met (healthy individual)	0.88	Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
328	Crohn's disease with improved perianal fistula treated with infliximab (healthy individual)	0.91	Patient/Community (32 Crohn's disease Patients and 20 healthy individuals)	Standard gamble	
Esophagus and Stomach					
245	Moderate-to-severe-Gastroesophageal reflux disease symptoms	0.95	Author	Author/clinician judgement	
245	Poor surgical outcome (laparoscopic Nissen fundoplication)	0.95	Author	Author/clinician judgement	
245	Mild Gastroesophageal reflux disease symptoms	0.98	Author	Author/clinician judgement	
363	Ulcer	0.79	Clinician (2 gastroenterologists, 2 general internists and a clinical psychologist)	Author/clinician judgement	
363	Heartburn/ regurgitation	0.82	Clinician (2 gastroenterologists, 2 general internists and a clinical psychologist)	Author/clinician judgement	
Liver General					
512	Chronic rejection post orthotopic liver transplant	0.5	Author	Author/clinician judgement	
512	Severe opportunistic infection in setting of CMV disease post orthotopic liver transplant	0.5	Author	Author/clinician judgement	
512	CMV disease post orthotopic liver transplant	0.75	Author	Author/clinician judgement	
512	Acute rejection post orthotopic liver transplant	0.9	Author	Author/clinician judgement	
512	Healthy post orthotopic liver transplant	1	Author	Author/clinician judgement	
512	CMV infection post orthotopic liver transplant	1	Author	Author/clinician judgement	

Gastrointestinal Procedures and Surgeries						
297	1 week post-open groin hernia repair	0.68		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
297	1 week post-laparoscopic groin hernia repair	0.74		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
297	1 month post-open groin hernia repair	0.79		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
297	1 month post-laparoscopic groin hernia repair	0.82		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
297	3 months post-laparoscopic groin hernia repair	0.85		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
297	3 months post-open groin hernia repair	0.86		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 928 patients with a groin hernia)
458	Esophagectomy	0.97		Patient (patients who had undergone esophagectomy at Duke University n not given)	Time trade off	
264	Liver biopsy with complication	0.97		Clinician (Expert panel n not given)	Standard gamble and Time trade off	
264	Liver biopsy without complication	0.986		Clinician (Expert panel n not given)	Standard gamble and Time trade off	
10. Diseases of the Genitourinary System						
Renal Failure						
335	ESRD	0.61		Not stated	Unknown	
246	End-stage renal failure	0.576		Not stated	Unknown	

273	ESRD	0.63	Community	Rating scale □ Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
335	ESRD	0.61	Not stated	Unknown	
386	End Stage Renal Disease	0.61	Not stated	Unknown	
270	End-Stage Renal disease	0.49	Not stated	Unknown	
	Kidney Dialysis				
381	Dialysis-dependent renal failure	0.68	Not stated	Unknown	
380	Dialysis-dependent renal failure	0.68	Not stated	Unknown	
336	Patients with end stage renal disease treated with full care center hemodialysis	0.66	Community	Standard gamble; Time trade off; Rating scale	EQ5D (EuroQoL) (given to 165 dialysis patients)
336	Patients with end stage renal disease treated with limited care center hemodialysis	0.81	Community	Standard gamble; Time trade off; Rating scale	EQ5D (EuroQoL) (given to 165 dialysis patients)
336	Patients with end stage renal disease treated with continuous ambulatory peritoneal dialysis	0.71	Community	Standard gamble; Time trade off; Rating scale	EQ5D (EuroQoL) (given to 165 dialysis patients)
336	Patients with end stage renal disease treated with continuous cycling peritoneal dialysis	0.81	Community	Standard gamble; Time trade off; Rating scale	EQ5D (EuroQoL) (given to 165 dialysis patients)
	Kidney Transplant				
336	Patients with kidney transplants	0.9	Community	Standard gamble; Time trade off; Rating scale	EQ5D (EuroQoL) (given to 165 dialysis patients)
	Other Genito-Urinary				
263	60yo males with normal age-related degree of erectile dysfunction	0.87	Community	Time trade off; Rating scale	QWB Scale (Beaver Dam Health Outcomes Study)

263	Utility of symptomatic erectile dysfunction (assuming a baseline of 1)	0.74		Community	Time trade off; Rating scale	QWB Scale (Beaver Dam Health Outcomes Study)
263	Acute Sildenafil-related morbidity	0.3		Author	Author/Clinical judgement	
263	Chronic Sildenafil-related morbidity	0.5		Author	Author/Clinical judgement	
294	Mean utility gain from sildenafil for patients with erectile dysfunction	0.11		Community (354 people from the Rotterdam telephone directory)	Time trade off	
346	Menorrhagia	0.5	.46-.54	Patient (60 women referred in Bristol UK for uncomplicated menorrhagia)	Time trade off	
346	Premenopausal following recovery from successful transcervical resection of the endometrium (TCRE)	0.73	.69-.77	Patient (60 women referred in Bristol UK for uncomplicated menorrhagia)	Time trade off	
346	Premenopausal following recovery from abdominal hysterectomy (AH)	0.86	.83-.89	Patient (60 women referred in Bristol UK for uncomplicated menorrhagia)	Time trade off	
346	Covalescence following TCRE	0.76	.72-.80	Patient (60 women referred in Bristol UK for uncomplicated menorrhagia)	Time trade off	
346	Covalescence following AH	0.74	.69-.79	Patient (60 women referred in Bristol UK for uncomplicated menorrhagia)	Time trade off	
404	Overactive bladder with <9 micturitions plus leakages per day	0.742		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients in Swedish willingness to pay survey

404	Overactive bladder with 9-11 micturitions plus leakages per day	0.712		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients in Swedish willingness to pay survey
404	Overactive bladder with 12-14 micturitions plus leakages per day	0.676		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients in Swedish willingness to pay survey
404	Overactive bladder with 15-17 micturitions plus leakages per day	0.64		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients in Swedish willingness to pay survey
404	Overactive bladder with ≥ 18 micturitions plus leakages per day	0.598		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients in Swedish willingness to pay survey
454	Symptomatic Benign Prostatic Hyperplasia (BPH) - risk-averse individual	0.982		Patient (13 men with moderate to severe BPH)	Standard gamble	
454	Symptomatic BPH - non-risk-averse individual	0.944		Patient (13 men with moderate to severe BPH)	Standard gamble	
454	Alpha blocker therapy for BPH - risk-averse individual	0.998		Patient (13 men with moderate to severe BPH)	Standard gamble	
454	Alpha blocker therapy for BPH - non-risk-averse individual	0.946		Patient (13 men with moderate to severe BPH)	Standard gamble	
454	Thermotherapy for BPH - risk-averse individual	0.993		Patient (13 men with moderate to severe BPH)	Standard gamble	
454	Thermotherapy for BPH - non-risk-averse individual	0.953		Patient (13 men with moderate to severe BPH)	Standard gamble	

529	Patients with history of urge incontinence now normal	0.74	.63-.85	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients 455 patients, 18-91 years
529	Patient with mild urge incontinence	0.72	.69-.75	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients 455 patients, 18-91 years
529	Patient with moderte urge incontinence	0.69	.65-.73	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients 455 patients, 18-91 years
529	Patient with severe urge incontinece	0.61	.55-.67	Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients 455 patients, 18-91 years
11. Pregnancy, Childbirth, and Perparium						
Maternal and Child Health (Perinatal)						
343	Value of maternal and child health services in urban Dhaka, Bangladesh	0.53		Author	Author/clinician judgement	
406	Successful trial of labor after previous cesarean section	0.65		Community	Rating scale	QWB Scale used by the author
406	Elective repeat cesarean delivery	0.55		Community	Rating scale	QWB Scale used by the author
406	Hysterectomy	0.51		Community	Rating scale	QWB Scale used by the author
406	Uterine rupture	0.51		Community	Rating scale	QWB Scale used by the author
406	Infection	0.52		Community	Rating scale	QWB Scale used by the author

406	Fecal incontinence	0.71		Community	Rating scale	QWB Scale used by the author
406	Urinary incontinence	0.71		Community	Rating scale	QWB Scale used by the author
12. Diseases of the Skin and Subcutaneous Tissue						
Skin Diseases (Non-Cancer)						
280	Patient with mild psoriasis		.74-.85	Patient/Clinician/Community (15 patients with psoriasis, 16 dermatologists, and 27 members of society)	Rating scale	
280	Patient with moderate psoriasis		.55-.70	Patient/Clinician/Community (15 patients with psoriasis, 16 dermatologists, and 27 members of society)	Rating scale	
280	Patient with severe psoriasis		.36-.47	Patient/Clinician/Community (15 patients with psoriasis, 16 dermatologists, and 27 members of society)	Rating scale	
Upper Extremity						
416	First year following wrist fracture in post-menopausal woman with h/o fracture	0.9		Patient (42 women with osteoporosis, n not given)	Standard gamble	
428	Transection of median nerve following carpal tunnel release	0.511		Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
428	Scar tenderness following carpal tunnel release (6 months)	0.693		Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	

428	Persistent carpal tunnel symptoms despite surgical release (rest of life)	0.698	Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
428	Wound infection following carpal tunnel release (3 weeks)	0.75	Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
428	No complication following open carpal tunnel release (6mo)	0.781	Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
428	Finger numbness following carpal tunnel release (3 months)	0.813	Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
428	No complication following endoscopic carpal tunnel release (6mo)	0.827	Clinician (Surgery Residents/Hand Therapists/Nurses n=21)	Rating scale	
507	Year with forearm fracture	0.95	Clinician (not stated who)	Author/clinician judgement	
Hip					
291	Nursing home following severe disability from osteoporotic fracture	0.4	Author	Author/clinician judgement	
291	Well without fracture (age-adjusted for a 55 y.o postmenopausal woman)	0.9	Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
291	Hip fracture	0.6	Patient (n not given)	Time trade off	
291	Other fracture	0.8	Patient (n not given)	Time trade off	
416	First year following hip fracture in post-menopausal woman with h/o fracture	0.4	Patient (42 women with osteoporosis, n not given)	Standard gamble	
416	Second year following hip fracture in post-menopausal woman with h/o fracture	0.5	Patient (42 women with osteoporosis, n not given)	Standard gamble	
301	Hip fracture from osteoporosis	0.28	Author	Unknown	
316	Patients needing total hip replacement	0.5	Patient (54 patients needing primary total hip replacement)		QoL score on Nottingham Health Profile (non-preference) converted

316	Patients after total hip replacement	0.86		Patient (54 patients needing primary total hip replacement)		QoL score on Nottingham Health Profile (non-preference) converted
410	1st year post hip fracture age 75-84	0.43		Community	Time trade off/Rating scale	EQ5D (EuroQoL) (Not stated to whom it was given)
410	1st year post hip fracture age 85+	0.43		Community	Time trade off/Rating scale	EQ5D (EuroQoL) (Not stated to whom it was given)
410	1st year post hip fracture age 65-74	0.59		Community	Time trade off/Rating scale	EQ5D (EuroQoL) (Not stated to whom it was given)
410	1st year post hip fracture age 50-64	0.7		Community	Time trade off/Rating scale	EQ5D (EuroQoL) (Not stated to whom it was given)
416	Normal health postmenopausal woman with previous fracture	0.92		Patient (42 women with osteoporosis, n not given)	Standard gamble	
506	Resection arthroplasty	0.6		Community	Standard gamble □ Rating scale	Health Utilities Index given to staff orthopedic surgeons familiar with the management of infected THAs
506	Total hip arthroplasty with good function	0.93		Community	Standard gamble □ Rating scale	Health Utilities Index given to staff orthopedic surgeons familiar with the management of infected THAs
507	Year with hip fracture	0.8		Clinician (not stated who)	Author/clinician judgement	
521	First year after hip fracture (assuming a baseline of 1)	0.8		Not stated	Unknown	
521	Second year after hip fracture (assuming a baseline of 1)	0.9		Not stated	Unknown	
532	Hip fracture First year	0.613		Clinician	Unknown	
532	Hip fracture Subsequent years	0.915		Clinician	Unknown	
	Knee and Foot					

				<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>		
317	Activity Class I (poor) with anterior cruciate ligament tear	0.23		<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>	Rating scale	
317	Activity Class II with anterior cruciate ligament tear	0.32		<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>	Rating scale	

				<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>		
317	Activity Class III with anterior cruciate ligament tear	0.54		<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>	Rating scale	
317	Activity Class IV with anterior cruciate ligament tear	0.7		<p>Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)</p>	Rating scale	

				Community (285 undergraduate students enrolled in health and physical education classes at a Division II university in US, mean age 21.7 years, 131 male and 154 female; 130 regularly participated in mod or very stressful sports, 132 vigorous recreational or competitive level, and 48 did not participate in any sport regularly; 81 previous knee injury and 19 previous knee surgery)		
317	Activity Class V (excellent) with anterior cruciate ligament tear	1			Rating scale	
321	Diabetes with After healing with major amputation	0.31		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
321	Diabetes with Ongoing ulcer	0.44		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
321	Diabetes with After primary healing of foot ulcer	0.6		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
321	Diabetes with After healing with minor amputation	0.61		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
321	Diabetes with No foot ulcer	0.8		Community	Time trade off; Rating scale	EQ5D (EuroQoL) (3,104 patients, mean age 62)
	Spine					
416	First year following vertebral fracture in post-menopausal woman with h/o fracture	0.64		Patient (42 women with osteoporosis, n not given)	Standard gamble	

435	Paralysis resulting from c-spine fracture (assuming a baseline of 1)	0.516		Community	Rating scale; Standard gamble	Health Utilities Index given to clinicians
481	Spinal cord compression due to bony met from breast CA	0.2		Author	Author/clinician judgement	
442	Neurologic deficit by spinal cord or cauda equina injury	0.39		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Short-term complication of deep wound infection following laminectomy for 2 weeks	0.67		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Short-term complication of dural tear following laminectomy for two days	0.67		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Short-term medical complication following laminectomy for 7 days	0.67		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Chronic back pain (symptoms of spinal stenosis not improved)	0.79		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Neurologic deficit by nerve root injury	0.79		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Chronic bone graft donor site pain following laminectomy with fusion, 1st yr.	0.96		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)

442	Degenerative spondylolisthesis and spinal stenosis free of symptoms	0.97		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
442	Chronic bone graft donor site pain following laminectomy with fusion, subsequent yrs.	0.99		Community	Rating scale; Time trade off	QWB Scale (Beaver Dam Health Outcome Study, Fryback et al 1993)
507	Year with vertebral fracture	0.9		Clinician (not stated who)	Author/clinician judgement	
532	Vertebral fracture First year	0.704		Clinician	Unknown	
532	Vertebral fracture Subsequent years	0.858		Clinician	Unknown	
	General Musculoskeletal					
498	Skeletal Related Events SRE in patients with breast cancer with placebo	0.307		Community (25 female public volunteers median age 45, range 28-66, 68% married, 17% household income below Can \$30,000, 20% did not have children, 8% had received some form of chemo for cancer and 29% had had personal experience of a broken bone))	Time trade off	
498	Skeletal Related Events (SRE) in patients with breast cancer with pamidronate	0.455		Community (25 female public volunteers median age 45, range 28-66, 68% married, 17% household income below Can \$30,000, 20% did not have children, 8% had received some form of chemo for cancer and 29% had had personal experience of a broken bone))	Time trade off	

498	No Skeletal Related Events SRE in patients with breast cancer with placebo	0.563	Community (25 female public volunteers median age 45, range 28-66, 68% married, 17% household income below Can \$30,000, 20% did not have children, 8% had received some form of chemo for cancer and 29% had had personal experience of a broken bone))	Time trade off	
498	No Skeletal Related Events SRE in patients with breast cancer with pamidronate	0.644	Community (25 female public volunteers median age 45, range 28-66, 68% married, 17% household income below Can \$30,000, 20% did not have children, 8% had received some form of chemo for cancer and 29% had had personal experience of a broken bone))	Time trade off	
276	Well 60 y.o male with joint disease	1	Community	Time trade off Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
481	Surgery for pathologic fracture due to metastatic breast CA	0.4	Author	Author/clinician judgement	
481	Radiation therapy for bone metastases from breast CA	0.6	Author	Author/clinician judgement	
481	Pathologic fractures (due to breast CA) that are either asymptomatic or require only oral analgesics	0.8	Author	Author/clinician judgement	
507	Severly handicapped post-fracture	0.4	Clinician (not stated who)	Author/clinician judgement	
507	Near normal functioning post-fracture	0.9	Clinician (not stated who)	Author/clinician judgement	
	Geriatrics				

392	Hospital bed day for elderly patient with at least one of four geriatric conditions (depressive symptoms, urinary incontinence, falls, or functional impairment)	0.7		Community	Improvement in physical function translated into QWB score change using Beaver Dam health outcome study	SF-36/12, transformed given to patients, population not given
392	Restricted activity day for elderly patient with at least one of four geriatric conditions (depressive symptoms, urinary incontinence, falls, or functional impairment)	0.9		Community	Improvement in physical function translated into QWB score change using Beaver Dam health outcome study	SF-36/12, transformed given to patients, population not given
Infection						
276	Impaired (Major loss of joint function due to bacterial arthritis)	0.75		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
276	Non-fatal reaction to antibiotic prophylaxis for bacterial arthritis	0.989		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
276	Well 60 y.o male with joint disease	1		Community	Time trade off; Rating scale	EQ5D (EuroQoL) given to patients, 4907 patients with joint disease
Rheumatoid Arthritis						
296	Rheumatoid Arthritis- baseline- rating scale	0.55		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)

296	Monotherapy (sulphasalazine)-28 weeks-rating scale	0.7		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Combined treatment -28 weeks- rating scale	0.79		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Monotherapy (sulphasalazine)-56 weeks-rating scale	0.81		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Monotherapy (sulphasalazine)-28 weeks-standard gamble	0.82		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)

296	Combined treatment -56 weeks- rating scale	0.83		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Monotherapy (sulphasalazine)-56 weeks-standard gamble	0.83		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Monotherapy (sulphasalazine)-56 weeks-standard gamble	0.83		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
296	Combined treatment -28 weeks- standard gamble	0.86		Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)

296	Rheumatoid Arthritis- baseline- Standard gamble		0.76-0.78	Community	Standard gamble; Rating scale	Maastricht Utility Measurement Questionnaire (given to 156 Rheumatoid arthritis patients aged 18-70 y.o in the Netherlands)
502	GI perforation in a patient with Rheumatoid arthritis		0.5	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
502	GI bleeding in a patient with Rheumatoid arthritis		0.6	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
502	Rheumatoid arthritis that is well treated (assuming a baseline of 1)		0.94	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	

502	Ulcer (assuming a baseline of 1)	0.97	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
502	Withdrawn NSAID treatment (assuming a baseline of 1)	0.98	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
502	Dyspepsia (assuming a baseline of 1)	0.99	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
502	Diarrhea or abdominal pain (assuming a baseline of 1)	0.99	Author	Person trade off, based on a survey of 1,600 Rheumatoid patients in Oslo, Norway, and guidelines developed at the national Institute of Public Health of Norway	
386	Amputation Lower Extremity Amputation (LEA)	0.8	Not stated	Unknown	

						EQ5D (EuroQoL) (given to 2650 patients randomized to receive either oral anticoagulants or aspirin daily after infrainguinal bypass grafting surgery)
378	Amputation	0.43		Community	Time trade off; Rating scale	
380	Major amputation	0.8		Not stated	Unknown	
305	Amputation outcome (limb loss following vascular injury)	0.4		Not Stated	Unknown	
	14. Congenital Anomalies					
	Congenital Anomalies					
373	Low congenital anorectal malformation - untreated (i.e. serious obstipation and incontinence)	0.5		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 283 patients and their parents who had undergone treatent for congenital anorectal malformations)
373	Adult (>=16years old) status post surgical correction of congenital anorectal malformation	0.88		Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 283 patients and their parents who had undergone treatent for congenital anorectal malformations)

373	5-15years of age status post surgical correction of congenital anorectal malformation	0.89	Community	Rating scale; Time trade off	EQ5D (EuroQoL) (given to 283 patients and their parents who had undergone treatment for congenital anorectal malformations)
Congenital					
538	End-stage renal disease with occult spinal dysraphism	0.7	Clinician (treating physician)	Author/clinician judgement	
538	Severely Symptomatic with occult spinal dysraphism	0.8	Clinician (treating physician)	Author/clinician judgement	
538	Infection with occult spinal dysraphism	0.8	Clinician (treating physician)	Author/clinician judgement	
538	Surgery short-term with occult spinal dysraphism	0.85	Clinician (treating physician)	Author/clinician judgement	
538	Moderately Symptomatic with occult spinal dysraphism	0.9	Clinician (treating physician)	Author/clinician judgement	
538	Mildly Symptomatic with occult spinal dysraphism	0.95	Clinician (treating physician)	Author/clinician judgement	
538	Surgery no complications with occult spinal dysraphism	0.95	Clinician (treating physician)	Author/clinician judgement	
538	Asymptomatic with occult spinal dysraphism	1	Clinician (treating physician)	Author/clinician judgement	
17. Injury, Trauma and Poisoning					
Pain Management					
372	Associated with use of fentanyl transdermal system: Titration: withdrawal	0.53	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Noncompliance with long term use	0.53	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Need for incr. dose with long term use	0.53	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Uncontrolled pain	0.53	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Controlled pain	0.73	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Aberrant drug-nel. Behavior with long term use	0.8	Author	Author/clinician judgement	
372	Associated with use of fentanyl transdermal system: Over medication with long term use	0.8	Author	Author/clinician judgement	

394	Injury with Advanced Injury Severity score of 4 during each remaining year of life	0.927		Community	Rating scale	Functional Capacity Index (FCI) given to the community AIS3 n = 166,845, AIS4 n= 17,123 and AIS5 n=6,914.
445	Survival of penetrating colon trauma with permanent colostomy without complication	0.85		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Colostomy formation for severe penetrating colon trauma	0.86		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Colostomy formation for nonsevere penetrating colon trauma	0.89		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Survival of penetrating colon trauma with temporary colostomy without complication	0.93		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Resection and anastomosis for severe penetrating colon trauma	0.95		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Primary repair for severe penetrating colon trauma	0.96		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Complications while treating penetrating colon trauma (assume a baseline of 1)	0.98		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Primary repair for nonsevere penetrating colon trauma	0.98		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Resection and anastomosis for nonsevere penetrating colon trauma	0.98		Community (18 healthy volunteers age 14-35)	Rating scale	
445	Survival of penetrating colon trauma without colostomy or complication	1		Community (18 healthy volunteers age 14-35)	Rating scale	
	Vision					
237	Ocular injury caused by an orbital foreign body during MR imaging (assuming a baseline of 1)	0.76		Author	Rating Scale	
	18. General Health and Critical Care					
	General Health - Smokers					

429	Male ages 40-44;current smoker	0.82		Community	Rating scale	QWB Scale (not stated to whom it was given)
429	Female ages 40-44;current smoker	0.83		Community	Rating scale	QWB Scale (not stated to whom it was given)
429	Female ages 40-44; former smoker	0.87		Community	Rating scale	QWB Scale (not stated to whom it was given)
429	Male ages 40-44; former smoker	0.88		Community	Rating scale	QWB Scale (not stated to whom it was given)
429	Female ages 40-44; never smoked	0.88		Community	Rating scale	QWB Scale (not stated to whom it was given)
429	Male ages 40-44; never smoked	0.9		Community	Rating scale	QWB Scale (not stated to whom it was given)
Program/Organizational Interventions						
392	Hospital bed day	0.7		Community	Improvement in physical function translated into QWB score change using Beaver Dam health outcomes study results	SF-36/12, transformed (given to 351 community dwelling, elderly subjects with at least one of four geriatric conditions.)
392	Restricted activity	0.9		Community	Improvement in physical function translated into QWB score change using Beaver Dam health outcomes study results	SF-36/12, transformed (given to 351 community dwelling, elderly subjects with at least one of four geriatric conditions.)
Critical Care						
354	Type of admission to intensive care unit: medical (6 mo post discharge)	0.61		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)

354	Type of admission to intensive care unit: scheduled surgical (6 mo post discharge)	0.71		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Type of admission to intensive care unit: unscheduled surgical (6 mo post discharge)	0.7		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Severity score: SAPS II: <20 (6 mo post discharge)	0.64		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Severity score: SAPS II: 20 < 35 (6 mo post discharge)	0.68		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Severity score: SAPS II: 35 < 50 (6 mo post discharge)	0.57		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Severity score: SAPS II: > 50 (6 mo post discharge)	0.52		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Number of deficiencies (defined as organ failures requiring supply): 1 (6 mo post discharge)	0.66		Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)

354	Number of deficiencies (defined as organ failures requiring supply): 2 (6 mo post discharge)	0.55	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Number of deficiencies (defined as organ failures requiring supply):> 2 (6 mo post discharge)	0.65	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)
354	Intensive care admission with diagnosis Coma (6 mo post discharge)	0.67	Community	Time trade off; Rating scale	EQ5D (EuroQoL) to patients (121 patients, 6 months after discharge from ICU)

References

Reference #	Citation
229	Sweat M, O'Donnell C, O'Donnell L. Cost-effectiveness of a brief video-based HIV intervention for African American and Latino sexually transmitted disease clinic clients. <i>Aids</i> . Apr 13 2001;15(6):781-787.
231	Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. <i>Aids</i> . 1998;12(12):1503-1512.
233	Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. <i>Aids</i> . 2000;14(16):2543-2552.
236	Kallmes DF, Kallmes MH, Cloft HJ, Dion JE. Guglielmi detachable coil embolization for unruptured aneurysms in nonsurgical candidates: a cost-effectiveness exploration. <i>AJNR Am J Neuroradiol</i> . 1998;19(1):167-176.
237	Seidenwurm DJ, McDonnell CH, 3rd, Raghavan N, Breslau J. Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging. <i>AJNR Am J Neuroradiol</i> . 2000;21(2):426-433.
238	Bosch JL, Haaring C, Meyerovitz MF, Cullen KA, Hunink MG. Cost-effectiveness of percutaneous treatment of iliac artery occlusive disease in the United States. <i>AJR Am J Roentgenol</i> . 2000;175(2):517-521.
239	Kim HM, Kuntz KM, Cronan JJ. Optimal management strategy for use of compression US for deep venous thrombosis in symptomatic patients: a cost-effectiveness analysis. <i>Acad Radiol</i> . 2000;7(2):67-76.
240	Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective? <i>Acta Oncologica</i> . 2000;39(1):33-39.
241	Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. <i>Addiction</i> . 2001;96(9):1267-1278.
243	Mitton CR, Rose MS, Koshman ML, Sheldon RS. Cost-utility analysis of pacemakers for the treatment of vasovagal syncope. <i>Am J Cardiol</i> . 1999;84(11):1356-1359, A1358.
244	Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. <i>Am J Gastroenterol</i> . 1999;94(6):1593-1600.
245	Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i> . 2000;95(2):395-407.
246	Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. <i>Am J Kidney Dis</i> . 1998;31(1):49-54.
247	Douzdjian V, Ferrara D, Silvestri G. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. <i>Am J Kidney Dis</i> . 1998;31(5):794-802.
249	Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. <i>Am J Manag Care</i> . 1998;4(7):1004-1012.
250	Perone N, Bounameaux H, Perrier A. Comparison of four strategies for diagnosing deep vein thrombosis: a cost-effectiveness analysis. <i>Am J Med</i> . 2001;110(1):33-40.
251	Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. <i>Am J Med</i> . 2001;111(2):130-139.
252	Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. <i>Am J Med</i> . 2000;108(9):723-729.

253	Heidenreich PA, Masoudi FA, Maini B, et al. Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. Am J Med. 1999;107(3):198-208.			
254	Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome.	Am J Med. 2000;109(8):614-620.		
257	Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90(7):1100-1111.			
260	Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann Intern Med. 1998;129(10):779-786.			
261	Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med. 1999;130(8):625-636.			
263	Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med. 2000;132(12):933-937.			
264	Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med. 2000;133(9):665-675.			
265	Chervin RD, Murman DL, Malow BA, Totten V. Cost-utility of three approaches to the diagnosis of sleep apnea: polysomnography, home testing, and empirical therapy. Ann Intern Med. 1999;130(6):496-505.			
267	Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135(10):870-883.			
268	Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann Intern Med. 2001;134(5):345-360.			
269	Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med. 2000;133(11):864-876.			
270	Rosen AB, Fowler VG, Jr., Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia.	Ann Intern Med. 1999;130(10):810-820.		
271	Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain. Ann Intern Med. 1999;130(9):709-718.			
273	Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131(9):660-667.			
274	Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132(10):780-787.			
275	Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130(10):800-809.			
276	Krijnen P, Kaandorp CJ, Steyerberg EW, van Schaardenburg D, Moens HJ, Habbema JD. Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis. Ann Rheum Dis. 2001;60(4):359-366.			
277	Sollano JA, Rose EA, Williams DL, et al. Cost-effectiveness of coronary artery bypass surgery in octogenarians. Ann Surg. 1998;228(3):297-306.			
278	Dranitsaris G, Leung P, Mather J, Oza A. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs. 2000;11(7):591-601.			
280	Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study. Arch Dermatol. 1998;134(12):1602-1608.			
281	Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry. Jul 1998;55(7):645-651.			
282	Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med. 2001;161(4):554-561.			
283	Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med. 2000;160(18):2773-2778.			
284	Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med. Jan 8 2001;161(1):111-120.			
285	Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158(15):1669-1677.			
287	Palmer CS, Niparko JK, Wyatt JR, Rothman M, de Lissovoy G. A prospective study of the cost-utility of the multichannel cochlear implant. Arch Otolaryngol Head Neck Surg. 1999;125(11):1221-1228.			
288	Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000;126(8):935-939.			
290	Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000;43(8):1841-1848.			
291	Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum. 2000;43(9):1967-1975.			
292	Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord. 2001;1(1):2.			
293	Forbes RB, Lees A, Waugh N, Swingle RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. Bmj. 1999;319(7224):1529-1533.			
294	Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of sildenafil compared with papaverine-phenolamine injections. Bmj. 2000;320(7243):1165-1168.			
295	Phillips CJ. Livial: an economic appraisal. Br J Obstet Gynaecol. 1999;106(Suppl 19):22-28.			
296	Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, 1109.	methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group.		
		Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol. Oct 1998;37(10):1102-1109.		
297	Medical Research Council Laparoscopic Groin Hernia Trial Group. Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial.[comment]. British Journal of Surgery. 2001;88(5):653-661.			
301	Grann VR, Sundararajan V, Jacobson JS, et al. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J. 2000;6(3):169-178.			
302	Cleland JG, Walker A. Therapeutic options and cost considerations in the treatment of ischemic heart disease. Cardiovasc Drugs Ther. 1998;12(Suppl 3):225-232.			
303	Anderson AN, Moodley I, Kropman K. A South African pharmaco-economic analysis of the Acute Infarction Ramipril Efficacy (AIRE) Study. Cardiovasc J S Afr. 2000;11(2):89-94.			
304	Brothers TE, Rios GA, Robison JG, Elliot BM. Justification of intervention for limb-threatening ischemia: a surgical decision analysis. Cardiovasc Surg. 1999;7(1):62-69.			
305	Keen JD, Keen RR. The cost-effectiveness of exclusion arteriography in extremity trauma. Cardiovasc Surg. 2001;9(5):441-447.			

306	Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. <i>Chest</i> . 1998;113(1):124-130.		
307	Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. <i>Chest</i> . Jan 1998;113(1):131-141.		
308	Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. <i>Chest</i> . 1998;114(5 Suppl):699S-714S.		
309	Nichol G, Hallstrom AP, Ornato JP, et al. Potential cost-effectiveness of public access defibrillation in the United States. <i>Circulation</i> . 1998;97(13):1315-1320.		
310	Calkins H, Bigger JT, Jr., Ackerman SJ, et al. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. <i>Circulation</i> . 2000;101(3):280-288.		
311	Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatid in patients with non-ST-elevation acute coronary syndromes. <i>Circulation</i> . Feb 1 2000;101(4):366-371.		
312	Dodek P, Phillips P. Questionable history of immediate-type hypersensitivity to penicillin in Staphylococcal endocarditis: treatment based on skin-test results vers-us empirical alternative treatment--A decision analysis. <i>Clin Infect Dis</i> . 1999;29(5):1251-1256.		
315	Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. <i>Clinical Infectious Diseases</i> . 2000;30(1):157-164.		
316	Garellick G, Malchau H, Herberts P, Hansson E, Axelsson H, Hansson T. Life expectancy and cost utility after total hip replacement. <i>Clin Orthop</i> . Jan 1998(346):141-151.		
317	Gottlob CA, Baker CL, Jr., Pellissier JM, Colvin L. Cost effectiveness of anterior cruciate ligament reconstruction in young adults. <i>Clin Orthop</i> . 1999(367):272-282.		
318	Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. <i>Curr Opin Ophthalmol</i> . 2000;11(3):175-179.		
319	Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. <i>Curr Opin Ophthalmol</i> . 2001;12(3):230-234.		
320	Chen TH, Yen MF, Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. <i>Diabetes Res Clin Pract</i> . 2001;54(Suppl 1):S37-42.		
321	Ragnarson Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. <i>Diabetologia</i> . 2001;44(11):2077-2087.		
322	Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. <i>Dis Colon Rectum</i> . 2000;43(12):1695-1701; discussion 1701-1693.		
323	Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ryden L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. <i>Eur Heart J</i> . May 2000;21(9):733-739.		
325	Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. <i>Eur J Clin Pharmacol</i> . 1998;53(6):421-427.		
327	Andersson A, Strom K, Brodin H, et al. Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis. <i>Eur Respir J</i> . Dec 1998;12(6):1284-1289.		
328	Arseneau KO, Cohn SM, Cominelli F, Connors AF, Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. <i>Gastroenterology</i> . 2001;120(7):1640-1656.		
329	Trueman P, Youle M, Sabin CA, Miners AH, Beck EJ. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. <i>HIV Clin Trials</i> . 2000;1(1):27-35.		
330	Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. <i>HIV Med</i> . 2001;2(1):52-58.		
331	Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. <i>Haemophilia</i> . 2001;7(3):279-285.		
335	van Os N, Niessen LW, Bilo HJ, Casparie AF, van Hout BA. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. <i>Health Policy</i> . 2000;51(3):135-147.		
336	de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. <i>Health Policy</i> . 1998;44(3):215-232.		
337	Zwanziger J, Szilagyi PG, Kaul P. Evaluating the benefits of increasing measles immunization rates. <i>Health Serv Res</i> . 2001;36(5):885-909.		
339	Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. <i>Hepatology</i> . 1999;29(2):548-552.		
340	Marchand R, Tousignant P, Chang H. Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly. <i>Int J Epidemiol</i> . 1999;28(3):563-570.		
342	Stigum H, Magnus P, Samdal HH, Nord E. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. <i>Int J Epidemiol</i> . 2000;29(6):1076-1084.		
343	Routh S, Barkat e K. An economic appraisal of alternative strategies for the delivery of MCH-FP services in urban Dhaka, Bangladesh. <i>Int J Health Plann Manage</i> . 2000;15(2):115-132.		
344	Robinson MB, Thompson E, Black NA. A model for estimating the cost-utility of clinical audit. The example of thrombolysis for suspected acute myocardial infarction. <i>Int J Technol Assess Health Care</i> . 1998;14(1):161-171.		
345	van Enckevort PJ, TenVergert EM, Bonsel GJ, et al. Technology assessment of the Dutch Lung Transplantation Program. <i>Int J Technol Assess Health Care</i> . 1998;14(2):344-356.		
346	Sculpher M. A cost-utility analysis of abdominal hysterectomy versus transcervical endometrial resection for the surgical treatment of menorrhagia. <i>Int J Technol Assess Health Care</i> . 1998;14(2):302-319.		
350	Carter R, Hailey D. Economic evaluation of the cochlear implant. <i>Int J Technol Assess Health Care</i> . 1999;15(3):520-530.		
351	Scharfstein JA, Paltiel AD, Weinstein MC, et al. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. <i>Int J Technol Assess Health Care</i> . 1999;15(3):531-547.		
354	Sznajder M, Aegerter P, Launois R, Merliere Y, Guidet B, CubRea. A cost-effectiveness analysis of stays in intensive care units. <i>Intensive Care Med</i> . 2001;27(1):146-153.		
358	Pedretti RF, Migliori GB, Mapelli V, Daniele G, Podrid PJ, Tamarin R. Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. <i>J Am Coll Cardiol</i> . 1998;31(7):1481-1489.		
359	Hamel MB, Phillips RS, Davis RB, et al. Are aggressive treatment strategies less cost-effective for older patients? The case of ventilator support and aggressive care for patients with acute respiratory failure. <i>J Am Geriatr Soc</i> . 2001;49(4):382-390.		
360	Seto TB, Taira DA, Manning WJ. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis. <i>J Am Soc Echocardiogr</i> . 1999;12(6):508-516.		
362	Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. <i>J Clin Oncol</i> . 1998;16(3):1022-1029.		
363	Heudebert GR, Centor RM, Klapow JC, Marks R, Johnson L, Wilcox CM. What is heartburn worth? A cost-utility analysis of management strategies. <i>J Gen Intern Med</i> . 2000;15(3):175-182.		
364	Lavender M, Craig N, Kerr R, Howel D. Computer simulation to estimate the effectiveness of carotid endarterectomy. <i>J Health Serv Res Policy</i> . 1998;3(1):6-11.		
365	Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? <i>J Hypertens</i> . 2001;19(1):149-155.		

365	Gray AM. ALS/MND and the perspective of health economics. J Neurol Sci. 1998;160(Suppl 1):S2-5.		
368	Tavakoli M, Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci. 2001;191(1-2):95-102.		
369	Gaetani P, Rodriguez y Baena R, Klersy C, Adinolfi D, Infuso L. A cost-effectiveness analysis on different surgical strategies for intracranial aneurysms. J Neurosurg Sci. 1998;42(2):69-78.		
370	Derdeyn CP, Gage BF, Grubb RL, Jr., Powers WJ. Cost-effectiveness analysis of therapy for symptomatic carotid occlusion: PET screening before selective extracranial-to-intracranial bypass versus medical treatment.	J Nucl Med. 2000;41(5):800-807.	
371	Marin MG, Van Lieu J, Yee A, Bonner E, Glied S. Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers. J Occup Environ Med. 1999;41(9):754-760.		
372	Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001;21(2):129-143.		
373	Poley MJ, Stolk EA, Langemeijer RA, Molenaar JC, Busschbach JJ. The cost-effectiveness of neonatal surgery and subsequent treatment for congenital anorectal malformations. J Pediatr Surg. 2001;36(10):1471-1478.		
375	Keen JD, Dunne PM, Keen RR, Langer BG. Proximity arteriography: cost-effectiveness in asymptomatic penetrating extremity trauma. J Vasc Interv Radiol. 2001;12(7):813-821.		
376	Schermerhorn ML, Birkmeyer JD, Gould DA, Cronenwett JL. Cost-effectiveness of surgery for small abdominal aortic aneurysms on the basis of data from the United Kingdom small aneurysm trial. J Vasc Surg.	2000;31(2):217-226.	
377	Yin D, Carpenter JP. Cost-effectiveness of screening for asymptomatic carotid stenosis. J Vasc Surg. 1998;27(2):245-255.		
378	Oostenbrink JB, Tangelder MJ, Busschbach JJ, et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. J Vasc Surg. Aug 2001;34(2):254-262.		
379	Patel ST, Haser PB, Korn P, Bush HL, Jr., Deitch JS, Kent KC. Is carotid endarterectomy cost-effective in symptomatic patients with moderate (50% to 69%) stenosis? J Vasc Surg. 1999;30(6):1024-1033.		
380	Patel ST, Haser PB, Bush HL, Jr., Kent KC. The cost-effectiveness of endovascular repair versus open surgical repair of abdominal aortic aneurysms: A decision analysis model. J Vasc Surg. 1999;29(6):958-972.		
381	Patel ST, Korn P, Haser PB, Bush HL, Jr., Kent KC. The cost-effectiveness of repairing ruptured abdominal aortic aneurysms. J Vasc Surg. 2000;32(2):247-257.		
382	Bonds DE, Freedberg KA. Cost-effectiveness of prenatal screening for postpartum thyroiditis. J Womens Health Gend Based Med. 2001;10(7):649-658.		
383	Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. Jama. 2000;284(21):2748-2754.		
384	Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. Jama. 2000;283(7):889-896.		
385	Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. Jama. 2000;284(7):850-856.		
386	Anonymous. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. Jama. 1998;280(20):1757-1763.		
388	Schoenbaum M, Unutzer J, Sherbourne C, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. Jama. Sep 19 2001;286(11):1325-1330.		
389	Freedberg KA, Scharfstein JA, Seage GR, 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. Jama. 1998;279(2):130-136.		
390	Groeneveld PW, Kwong JL, Liu Y, et al. Cost-effectiveness of automated external defibrillators on airlines. Jama. 2001;286(12):1482-1489.		
391	O'Neill C, O'Donoghue GM, Archbold SM, Normand C. A cost-utility analysis of pediatric cochlear implantation. Laryngoscope. 2000;110(1):156-160.		
392	Keeler EB, Robalino DA, Frank JC, Hirsch SH, Maly RC, Reuben DB. Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care. 1999;37(12):1199-1206.		
394	Redelmeier DA, Weinstein MC. Cost-effectiveness of regulations against using a cellular telephone while driving. Med Decis Making. 1999;19(1):1-8.		
395	Paltiel AD, Scharfstein JA, Seage GR, 3rd, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998;18(2 Suppl):S93-105.		
400	Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52(6):1138-1145.		
401	Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology. 2001;57(4):663-671.		
402	Johnston SC, Gress DR, Kahn JG. Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. Neurology. 1999;52(9):1806-1815.		
403	Fagan SC, Morgenstern LB, Pettita A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. Apr 1998;50(4):883-890.		
404	Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. NeuroUrol Urodyn. 1998;17(6):599-611.		
406	Chung A, Macario A, El-Sayed YY, Riley ET, Duncan B, Druzin ML. Cost-effectiveness of a trial of labor after previous cesarean. Obstet Gynecol. 2001;97(6):932-941.		
407	Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.	Ophthalmology. 2001;108(11):2051-2059.	
408	Brown GC, Brown MM, Sharma S, Brown H, Tasman W. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology. 2000;107(7):1374-1380.		
410	Jonsson B, Kanis J, Dawson A, Oden A, Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int. 1999;10(3):193-199.		
411	Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J. 2000;19(1):23-30.		
412	Brown GC, Brown MM, Sharma S, Tasman W, Brown HC. Cost-effectiveness of treatment for threshold retinopathy of prematurity. Pediatrics. 1999;104(4):e47.		
413	Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinus DF, Patrick DL. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics. Feb 1999;15(2):179-195.		
414	Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics. 2000;18(1):45-53.		
415	Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000;17(6):611-620.		
416	Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics.	2001;19(5 Pt 2):565-575.	
417	Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics. 2000;18(2):95-104.		
418	Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics.	1999;16(5 Pt 2):577-593.	
419	Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001;19(3):293-301.		

420	Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibiotic care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. <i>Pharmacoeconomics</i> . Nov 1999;16(5 Pt 1):499-520.		
422	Shimbo T, Hira K, Takemura M, Fukui T. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. <i>Pharmacoeconomics</i> . 2001;19(8):875-886.		
423	Sinclair SE, Frighetto L, Loewen PS, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. <i>Pharmacoeconomics</i> . 2001;19(9):927-936.		
424	Bona M, Santini F, Rivolta G, Grossi E, Grilli R. Cost effectiveness of screening for subclinical hypothyroidism in the elderly. A decision-analytical model. <i>Pharmacoeconomics</i> . 1998;14(2):209-216.		
426	Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. <i>Pharmacoeconomics</i> . 2001;19(11):1091-1102.		
427	Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. <i>Pharmacoepidemiol Drug Saf</i> . 2001;10(2):85-94.		
428	Chung KC, Walters MR, Greenfield ML, Chernen ME. Endoscopic versus open carpal tunnel release: a cost-effectiveness analysis. <i>Plast Reconstr Surg</i> . 1998;102(4):1089-1099.		
429	Tengs TO, Osgood ND, Chen LL. The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model. <i>Prev Med</i> . 2001;33(6):558-570.		
432	Marchetti M, Quaglino S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. <i>Qjm</i> . 2001;94(7):365-372.		
433	Hrung JM, Langlotz CP, Orel SG, Fox KR, Schnall MD, Schwartz JS. Cost-effectiveness of MR imaging and core-needle biopsy in the preoperative work-up of suspicious breast lesions. <i>Radiology</i> . 1999;213(1):39-49.		
434	Jager GJ, Severens JL, Thornbury JR, de La Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used?—A decision analytic approach. <i>Radiology</i> . 2000;215(2):445-451.		
435	Blackmore CC, Ramsey SD, Mann FA, Deyo RA. Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. <i>Radiology</i> . 1999;212(1):117-125.		
436	McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. <i>Radiology</i> . 2000;217(1):58-68.		
437	Bosch JL, Tetteroo E, Mali WP, Hunink MG. Iliac arterial occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Dutch Iliac Stent Trial Study Group. <i>Radiology</i> . 1998;208(3):641-648.		
438	rown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis. <i>Retina</i> . 2000;20(4):331-337.		
440	Bovier PA, Wyss K, Au HJ. A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. <i>Soc Sci Med</i> . 1999;48(9):1205-1220.		
442	Kuntz KM, Snider RK, Weinstein JN, Pope MH, Katz JN. Cost-effectiveness of fusion with and without instrumentation for patients with degenerative spondylolisthesis and spinal stenosis. <i>Spine</i> . 2000;25(9):1132-1139.		
444	Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. <i>Stroke</i> . 1998;29(6):1083-1091.		
445	Brasel KJ, Borgstrom DC, Weigelt JA. Management of penetrating colon trauma: a cost-utility analysis. <i>Surgery</i> . 1999;125(5):471-479.		
446	Patel ST, Kuntz KM, Kent KC. Is routine duplex ultrasound surveillance after carotid endarterectomy cost-effective? <i>Surgery</i> . 1998;124(2):343-351; discussion 351-342.		
447	Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. <i>Thorax</i> . Oct 2001;56(10):779-784.		
448	Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. <i>Transfusion</i> . 2000;40(10):1182-1191.		
449	Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donation in reducing allogeneic blood transfusions in coronary artery bypass graft surgery. <i>Transfusion</i> . 2000;40(6):673-681.		
450	Sonnenberg FA, Gregory P, Yomtovian R, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. <i>Transfusion</i> . 1999;39(8):808-817.		
451	Kiberd BA, Larson T. Estimating the benefits of solitary pancreas transplantation in nonuremic patients with type 1 diabetes mellitus: a theoretical analysis. <i>Transplantation</i> . 2000;70(7):1121-1127.		
454	Blute M, Ackerman SJ, Rein AL, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II—results. <i>Urology</i> . 2000;56(6):981-987.		
456	Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. <i>Value Health</i> . 2001;4(4):316-328.		
457	Nuijten MJ. Assessment of clinical guidelines for continuation treatment in major depression. <i>Value Health</i> . 2001;4(4):281-294.		
458	Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. <i>Am J Gastroenterol</i> . 1994;89(5):670-680.		
460	Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. <i>Am J Gastroenterol</i> . 2000;95(7):1800-1811.		
462	Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. <i>Am J Med</i> . 2001;111(2):140-149.		
463	Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. <i>Jama</i> . 1999;281(19):1822-1829.		
464	Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. <i>Ann Intern Med</i> . 1999;130(2):97-107.		
465	Liljegren G, Karlsson G, Bergh J, Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. <i>Ann Oncol</i> . Aug 1997;8(8):757-763.		
466	rown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. <i>Anticancer Drugs</i> . 1998;9(10):899-907.		
467	Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. <i>Blood</i> . 1998;92(11):4047-4052.		
468	Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. <i>Br J Cancer</i> . 1998;78(6):781-787.		
469	Grann VR, Jacobson JS, Whang W, et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. <i>Cancer J Sci Am</i> . 2000;6(1):13-20.		
471	Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. <i>Eur J Gastroenterol Hepatol</i> . 2001;13(5):483-488.		
472	Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. <i>Hepatology</i> . 1999;30(5):1318-1324.		
473	Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. <i>Hepatology</i> . 2001;33(5):1073-1079.		
476	Marks LB, Hardenbergh PH, Winer ET, Prosnitz LR. Assessing the cost-effectiveness of postmastectomy radiation therapy. <i>Int J Radiat Oncol Biol Phys</i> . 1999;44(1):91-98.		
477	Ng AK, Kuntz KM, Mauch PM, Weeks JC. Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. <i>Int J Radiat Oncol Biol Phys</i> . 2001;50(4):979-989.		

478	A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients. <i>Int J Radiat Oncol Biol Phys.</i> 2000 Nov 1;48(4):977-82.			
479	Kobelt G, Jonsson L, Henriksson F, Fredrikson S, Jonsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. <i>International Journal of Technology Assessment in Health Care.</i>	2000;16(3):768-780.		
480	King JT, Jr., Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. <i>J Clin Endocrinol Metab.</i> 1997;82(11):3625-3632.			
481	Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. <i>J Clin Oncol.</i> 2000;18(1):72-79.			
482	Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. <i>J Clin Oncol.</i>	1999;17(10):3082-3090.		
483	Hayman JA, Hillner BE, Harris JR, Pierce LJ, Weeks JC. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer. <i>J Clin Oncol.</i> 2000;18(2):287-295.			
485	Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. <i>J Clin Oncol.</i> 1998;16(3):979-985.			
487	Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? <i>J Med Screen.</i> 1999;6(3):124-131.			
488	Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. <i>J Natl Cancer Inst.</i> 2000;92(21):1731-1739.			
489	Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. <i>J Natl Cancer Inst.</i> 2000;92(16):1321-1329.			
490	Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. <i>J Neurol Neurosurg Psychiatry.</i> 2000;68(2):144-149.			
491	Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. <i>Jama.</i> 1998;280(24):2088-2093.			
492	Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. <i>Jama.</i> 1999;281(19):1822-1829.			
493	Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. <i>Leuk Lymphoma.</i> 2001;40(5-6):565-579.			
494	Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. <i>Leuk Lymphoma.</i>	2001;41(1-2):117-124.		
495	Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. <i>Med J Aust.</i> 1999;171(4):189-193.			
496	Medina LS, Kuntz KM, Pomeroy S. Children with headache suspected of having a brain tumor: a cost-effectiveness analysis of diagnostic strategies. <i>Pediatrics.</i> 2001;108(2):255-263.			
497	Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. <i>Pharmacoeconomics.</i> 2000;17(5):409-427.			
498	Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. <i>Support Care Cancer.</i> 1999;7(4):271-279.			
499	Orr RK, Col NF, Kuntz KM. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. <i>Surgery.</i>	1999;126(3):568-576.		
500	Patel ST, Haser PB, Bush HL, Jr., Kent KC. Is thrombolysis of lower extremity acute arterial occlusion cost-effective? <i>J Surg Res.</i> 1999;83(2):106-112.			
501	Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. <i>Transfusion.</i> 1999;39(5):479-487.			
502	Kristiansen IS, Kvien TK, Nord E. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis. <i>Arthritis Rheum.</i> 1999;42(11):2293-2302.			
503	Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. <i>Aids.</i> 1999;13(12):1549-1556.			
504	Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: A cost-effectiveness analysis. <i>J Am Acad Dermatol.</i> 1999;41(5 Pt 1):738-745.			
505	Yoshimoto Y, Wakai S. Cost-effectiveness analysis of screening for asymptomatic, unruptured intracranial aneurysms. A mathematical model. <i>Stroke.</i> 1999;30(8):1621-1627.			
506	Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. <i>Clin Infect Dis.</i> 2001;32(3):419-430.			
507	Willis M, Odegaard K, Persson U, Hedbrnat J, Mellstorm D, Hammar M. A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden. <i>Clinical Drug Investigation.</i> 2001;21(2):115-127.			
508	Lafuma A, Dreno B, Delaunay M, et al. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. <i>Eur J Cancer.</i> 2001;37(3):369-375.			
509	Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. <i>J Gen Intern Med.</i> 2000;15(1):31-37.			
511	Mavissakalian MR, Schmier JK, Flynn JA, Revicki DA. Cost-effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. <i>Pharmacoeconomics.</i> 2000;18(4):383-391.			
512	Das A. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients. <i>Hepatology.</i> 2000;31(2):311-317.			
513	Tengs TO, Berry DA. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. <i>Disease Management and Clinical Outcomes</i> 2000; 1: 15-24.			
514	Scheild DC, Hamm RM, Stevens JW. Cost-effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers. <i>Pharmacoeconomics.</i> 2000;18(4):355-368.			
516	Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis. <i>Thromb Haemost.</i> 2000;84(5):752-757.			
517	Gessner BD. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. <i>Vaccine.</i> 2000;18(15):1485-1494.			
518	Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. <i>Am J Med.</i> 2000;108(9):723-729.			
521	Jonsson B. Targeting high-risk populations. <i>Osteoporos Int.</i> 1998;8(Suppl 1):S13-16.			
522	Bennett CL, Golub RM, Calhoun EA, et al. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. <i>Internal Journal of Gynecological Cancer.</i> 1998;8:64-72.			
523	Lehmann DF, Medicis JJ. A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services. <i>J Clin Pharmacol.</i> 1998;38(9):783-791.			
524	Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty? <i>J Infect Dis.</i> 1998;178(Suppl 1):S85-90.			
525	Bonistalli L, Bardelli F, Costantini M, Trallori G, d'Albasio G, Messori A. Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis. <i>The Cancer Journal.</i>			

		1998;11(1):39-47.		
526	Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet. 1998;63(4):1160-1174.			
527	Nichol G, Dennis DT, Steere AC, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med. 1998;128(1):37-48.			
529	O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther.			
		2001;23(12):2038-2049.		
530	Dernovsek MZ, Prevolnik Rupel V, Rebolj M, Tavcar R. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry. 2001;16(8):474-482.			
531	Chau J, Cheung BM, McGhee SM, Lauder IJ, Lau CP, Kumana CR. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J. 2001;7(4):360-368.			
532	Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol. 2001;98(6):996-1003.			
533	Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111(8):614-621.			
534	Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation.			
		Dec 18 2001;104(25):3039-3045.		
535	Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for <i>Coccidioides immitis</i> . Emerg Infect Dis. 2001;7(5):797-806.			
537	Hollenbeak CS, Lowe VJ, Stack BC, Jr. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer. 2001;92(9):2341-2348.			
538	Medina LS, Crone K, Kuntz KM. Newborns with suspected occult spinal dysraphism: a cost-effectiveness analysis of diagnostic strategies. Pediatrics. 2001;108(6):E101.			
539	Balk EM, Zucker DR, Engels EA, Wong JB, Williams JW, Jr., Lau J. Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis. J Gen Intern Med. 2001;16(10):701-711.			
540	Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol. 2001;36(8):870-876.			